Protocol J2T-MC-KGBP( c)
An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult 
and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis and Skin of Color
[STUDY_ID_REMOVED]   
Approval Date: 29- Sep-2023 
CONFIDENTIAL  J2T-MC-KGBP (c) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_510884]  (LY3650150 ), unless such person s are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli L illy and Company requests consultation regarding release/redaction prior to any public release. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  
An Open-Label, 24 -Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult 
and Adolescent Participants with Moderate -to-Severe Atopic Dermatitis and Skin of Color 
Protocol Number:  J2T-MC-KGBP  
Amendment Number: c 
Compound: lebrikizumab (LY3650150)  
Brief  Title:  
A Study to Assess the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants  
with M oderate -to-Severe Atopic Dermatitis  and Skin of Color 
Study Phase:  3b 
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number : 
IND: 119866  
Approval Date:  Protocol Amendment ( c) Electronically  Signed and  Approved  by [CONTACT_10937].  
Document  ID: VV-CLIN -093431  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660803] Information will be provided separately . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660804]-2022  
Original Protocol  15-Aug-2022  
Amendment [c]  
Overall Rationale for the Amendment:  
The main rationale for this  amendment is to update the number of trial participants .  
Section # and Name  [CONTACT_510939]  
1.1. Synopsis, 1.2. Schema, 
and 4.1. Overall Design  Modified the 
enrollment goal to 
approximately 95 
participants  To enable exploratory biomarker 
analyses  
9.5. Sample Size 
Determination  Added rationale for 
increase in study 
participant 
enrollment  
10.11. Appendix 11 : 
Abbreviations and Definitions  Added definition for 
“SoA”  Clarification  
10.12. Appendix 12: Protocol 
Amendment History  Added amendment 
(b) summary of 
changes table  To update the amendment history  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
4 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ ............................ 12 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 13 
2. Introduction  ................................ ................................ ................................ ................... 21 
2.1. Study R ationale  ................................ ................................ ................................ ............... 21 
2.2. Background  ................................ ................................ ................................ ..................... 21 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 24 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......26 
4. Study Design  ................................ ................................ ................................ .................. 30 
4.1. Overall Design  ................................ ................................ ................................ ................ 30 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 30 
4.2.1.  Participant Input into Design  ................................ ................................ .......................... 31 
4.3. Justification for Dose  ................................ ................................ ................................ ......31 
4.4. End of Study De finition  ................................ ................................ ................................ ..31 
5. Study Population  ................................ ................................ ................................ ........... 32 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 32 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 33 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .35 
5.4. Screen Failures  ................................ ................................ ................................ ................ 36 
5.4.1.  Rescreening for Individuals Who Failed Screening  ................................ ....................... 36 
5.5. Criteria for Temporarily Delaying Enrollment/Administration of 
Study Inte rvention of a Participant  ................................ ................................ ................. 36 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 37 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 37 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 37 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 37 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 38 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 38 
6.5. Dose Modification  ................................ ................................ ................................ .......... 38 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 38 
6.7. Treatment of Overdo se ................................ ................................ ................................ ...39 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....39 
6.8.1.  Permitted Treatments and Procedures  ................................ ................................ ............ 39 
6.8.2.  Prohibited Treatments and Procedures  ................................ ................................ ........... 40 
6.8.3.  Non-Medicated Moisturizers  ................................ ................................ .......................... 41 
6.8.4.  Topi[INVESTIGATOR_81161]  ................................ ................................ .......41 
6.8.5.  Rescue Medicine for Atopic Dermatit is ................................ ................................ ......... 42 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 43 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 43 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
5 7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................. 44 
7.1.2.  Temporary Discontinuation of Study Intervention  ................................ ......................... 45 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_660805] to Follow up  ................................ ................................ ................................ ............ 46 
8. Study Assessments and Procedures ................................ ................................ ............. 47 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....47 
8.1.1. Eczema Area and Severity Index  ................................ ................................ .................... 47 
8.1.2.  Investigator’s Global Assessment (IGA)  ................................ ................................ ........ 47 
8.1.3.  Body Surface Area (BSA)  ................................ ................................ .............................. 48 
8.1.4.  Face -Investigator’s Global Assessment (F -IGA) ................................ ............................ [ADDRESS_660806]-inflammatory Dyschromia Scale (PDS)  ................................ ................................ .48 
8.1.6.  Patient -Oriented SCORing Atopic Dermatitis (PO -SCORAD)  ................................ .....48 
8.1.7.  Pruritus NRS  ................................ ................................ ................................ ................... 49 
8.1.8.  Sleep-Loss Scale  ................................ ................................ ................................ ............. 49 
8.1.9.  Skin Pain Numeric Rating Scale (Skin Pain NRS)  ................................ ......................... 49 
8.1.10.  Patient -Oriented Eczema Measure (POEM)  ................................ ................................ ...49 
8.1.11.  Dermatology Life Quality Index/Children’s Dermatology Life 
Quality Index (DLQI/cDLQI)  ................................ ................................ ......................... 49 
8.1.12.  Atopic Dermatitis Control Tool (ADCT)  ................................ ................................ .......50 
8.1.13.  Work P roductivity and Activity Impairment Questionnaire –
Atopic Dermatitis (WPAI -AD) ................................ ................................ ....................... [ADDRESS_660807]  ................................ ................................ ................. 59 
8.3.4.  Facial Dermatitis  ................................ ................................ ................................ ............. 59 
8.3.5.  Hypersensitivity  ................................ ................................ ................................ .............. 59 
8.3.6.  Injection Site Reactions  ................................ ................................ ................................ ..59 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 60 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 60 
8.6. Genetics  ................................ ................................ ................................ .......................... 60 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 60 
8.8. Immunog enicity Assessments ................................ ................................ ......................... 60 
8.9. Health Economics  ................................ ................................ ................................ ........... 61 
9. Statistical Considerations  ................................ ................................ ............................. 62 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....62 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 62 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 62 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
6 9.3.1. General Considerations  ................................ ................................ ................................ ...62 
9.3.2.  Primary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ ....63 
9.3.3.  Secondary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ 63 
9.3.4.  Exploratory Endpoint(s) Analysis ................................ ................................ ................... 63 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 63 
9.3.6.  Other Analyses  ................................ ................................ ................................ ................ 63 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 64 
9.5. Sample Size Determination  ................................ ................................ ............................ 64 
10. Supporting Documentation and Operational Considerations  ................................ ..66 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 66 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 66 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 66 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 67 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 67 
10.1.5.  Dissemination of Clinical Study Data ................................ ................................ ............. 68 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..68 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 70 
10.1.8.  Study and Site Start and Closure  ................................ ................................ .................... 70 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 71 
10.1.10.  Investigator Information  ................................ ................................ ................................ .71 
10.1.11.  Sample Retention  ................................ ................................ ................................ ............ 71 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 72 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event  ................................ ................................ ................................ ....74 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ [ADDRESS_660808] Complaints  ................................ ................................ ................... 78 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 79 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 81 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 81 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 82 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 82 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..82 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......85 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 86 
10.7.  Appendix 7: American Academy of Dermatology: Criteria for 
the Diagnosis and Assessment of Atopic Dermatitis  ................................ ...................... 88 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
7 10.8.  Appendix 8: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for  Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ............ 89 
10.9.  Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy  ................................ ........................... 90 
10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 92 
10.11.  Appendix 11: Abbreviations and Definitions  ................................ ................................ .94 
10.12.  Appendix 12: Protocol Amendment History  ................................ ................................ ..98 
11. References  ................................ ................................ ................................ .................... 101 
 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
8 1. Protocol Summary   
1.1. Synopsis   
Protocol Title:  
An Open -Label, 24 -Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult 
and Adolescent Participants with Moderate -to-Severe Atopic Dermatiti s and Skin of Color  
Brief  Title:  
A Study to Assess the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants 
with Moderate -to-Severe Atopic Dermatitis and Skin of Color  
Rationale : 
Atopic dermatitis  (AD)  is a chronic heterogeneous inflammatory disorder caused by [CONTACT_510911]. In patients  with AD, IL -13, a central 
pathogenic mediator in the disease , is overexpressed, driving multiple aspects of AD 
pathophysiology by [CONTACT_6561] T -helper Type 2 (Th2) cell inflammation and resulting in skin 
barrier dysfunction, itch, in fection , and lichenification. There is a paucity of data to guide 
diagnosis an d treatment  in populations traditionally under -represented in clinical trials, including 
patients with skin of color  (Price et al. 20 21; Chen et al . 2021 ). Compounding th is issue  is the 
complexity of diagnosing moderate -to-severe AD in this patient population , partially due to 
historical lack of representation in medical education resources and in some cases, limited 
exposure to patients with skin of color in medical training  (Ebede et al. 2005 ; Adelekun et al. 
2020 ; Ibraheim et al. 2021; Kurtti et al . 2022). The nuances of identifying erythema in patients 
with skin of color not only affect the accurate and timely diagnosis of AD but also confound the 
use of AD scales commonly used  in clinical trials  (Zhao  et al. 2015) . The aforementioned 
challenges may also  delay the use of systemic therapi[INVESTIGATOR_014] . 
Phase [ADDRESS_660809] demonstrated that lebrikizumab is effective in treating participants with  
moderate -to-severe AD. Subgroup analyses ha ve shown that the efficacy is comparable in 
participants of African  or Asian  descent . This study will complement  these finding s with a focus 
on patients with skin of color , will include objectives and endpoints commonly evaluated in AD 
clinical trials, and will additionally evaluate novel endpoints , including face-Investigator’s 
Global Assessment ( F-IGA), Patient -Oriented SCORing Atopic Dermatitis (PO-SCORAD ), 
Post-inflammatory Dyschromia Scale  (PDS) , and AD-related changes in erythema, 
hypopi[INVESTIGATOR_371] , and hyperpi[INVESTIGATOR_371].  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
9 Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary   
 To assess the effect of  lebrikizumab 250  mg 
Q2W in reduc ing the signs and symptoms of 
AD in participants with moderate -to-severe 
AD and skin of color   Percentage of participants  achieving EASI -75 
(≥75% reduction from baseline in EASI) at 
Week 16  
Secondary   
 To evaluate the effect of treatment with 
lebrikizumab in the signs and symptoms of 
AD and health outcome measures, in 
participants with moderate -to-severe AD and 
skin of color   Percentage of participants achieving EASI -75 at 
Week 24  
 Percentage of participants with an IGA score of 0 
or 1 and a reduction ≥2 points from baseline to 
Week s 16 and 24  
 Percentage change in EASI total from baseline to 
Week s 16 and 24  
 Change in EASI total from baseline to Week s 16 
and 24  
 Percentage of participants achieving EASI 90 at 
Week s 16 and 24  
 Percentage of participants with a Pruritus NRS of 
≥4 points at baseline who achieve a 4 -point 
reduction at Week s 16 and 24  
 Percentage of participants with a Pruritus NRS 
≥[ADDRESS_660810] 3 -point 
reduction at Week s 16 and 24  
 Percentage change in Pruritus NRS score  from 
baseline to Week s 16 and 24  
 Percentage of participants with a Sleep -Loss Scale 
score  of ≥2  points at baseline who achieve a 
2-point reduction at Week s 16 and 24  
 Percentage change in Sleep -Loss Scale score from 
baseline to Week s 16 and 24  
 Percentage of participants with a Skin Pain NRS of 
≥4 points at baseline who achieve a 4 -point 
reducti on from baseline to Week s 16 and 24  
 Change in POEM from baseline to Week s 16 and 
24 
 Change in DLQI from baseline to Week s 16 and 
24 in participants ≥ 16 years  at baseline  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
10  Change in cDLQI from baseline to Week s 16 and 
24 in participants < 16 years  at baseli ne  
 Percentage of participants with a DLQI of 
≥4 points at baseline who achieve a ≥4 -point 
improvement in DLQI at Week s 16 and 24 in 
participants ≥16 years at baseline  
Abbreviations: AD = atopic dermatitis; cDLQI = Children ’s DLQI ; DLQI = Dermatology Life  Quality Index ; EASI 
= Eczema Area and Severity Index ; IGA = Investigator’s Global Assessment ; NRS = numeric rating scale; 
POEM = Patient -Oriented Eczema Measure ; Q2W = once every 2 weeks . 
NOTE: Endpoints in the table above collected by [CONTACT_510912].  
Primary estimand  
The primary clinical question of interest is: What is the intervention effect in percentage of 
participants achieving  at least 75% improvement from baseline in Eczema Area and Severity 
Index (EASI ) after 16 weeks of lebrikizumab 250 mg Q2W  intervention in participants with  skin 
of color and  moderate -to-severe AD  who remain on study treatment until Week 16 . 
The estimand is described by [CONTACT_6570]:  
Population: participants with skin of color and moderate -to-severe AD who met inclusion and 
exclusion criteria  and who remained  on study treatment until Week 16 . Further details can be 
found in Section 5.  
Endpoint: whether participants achiev e at least 75% improvement from baseline in EASI  at 
Week 16 . 
Intercurrent events: There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment.  Therefore, 
participants who stay on study treatment thro ugh Week [ADDRESS_660811] an intercurrent event 
such as initiating rescue medication or permanently discontinuing treatment . 
Population -level summary: percentage of participants achieving EASI  75 response  at Week 16 . 
 
Secondary estimand(s)  
There is no secondary estimand plan ned at this stage ; however, additional estimand s might be 
specified in the statistical analysis plan . 
Overall Design : 
Study J2T-MC-KGBP ( KGBP ) is a single group treatment, open -label, Phase 3b  study , which is 
24 weeks in treatment duration. The study is designed to evaluate the safety and efficacy of 
lebrikizumab in adolescent and adult participants with skin of color and moderate -to-severe AD.  
During the 24-week Treatment  Period, approximately 95 participants wi ll receive treatment .  
 500 mg subcutaneous (SC) once every 2 weeks  (Q2W ) loading dose at baseline and 
Week 2, followed by 250  mg SC Q2W  until Week 16 . 
 Responders, defined as achieving IGA (0,1) or EASI -75 at Week 16, will receive 
250 mg SC once every 4 weeks ( Q4W). 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
11  Inadequate responders at Week 16 will continue to receive 250 mg SC Q2W . 
Brief Summary : 
The purpose of this study is to measure percentage of participants achieving EASI -75 at Week 
16 with lebrikizumab  in adolescent and adult participants with skin of color and moderate -to-
severe AD . 
Study details include  
● The planned study duration will be up to 38 weeks . 
● The treatment duration will be up to 24 weeks . 
● The visit frequency will be every [ADDRESS_660812] 2 visits, then every 4 weeks 
thereafter . 
Number of Participant s: 
Approximately 95 participants will be  enrolled  to study intervention . Because the inclusion of 
Black and African American patients is historically limited in clinical trials and given the focus 
of skin of color in this study, the majority of the patients in this study will be of Black or African 
American race (approximately 55 participants).  The remainder of the participants may be of any 
race other than White, with enrollment of up to 10% Asian participants.  
Intervention Groups  and Duration : 
Lebrikizumab  drug product  is provided as sterile liquid s and contain no preservatives.  
Intervention Name  [CONTACT_81294]  250 mg (125 mg/mL), 2  mL Solution  
Dosage Level  Loading Dose:  
Week 0 : 500 mg ( 2 injections of 250  mg) 
Week 2 : 500 mg ( 2 injections of 250  mg) 
 
Post-loading dose: 
Week 4 -16: 250 mg SC Q2W (1 injection  of 250  mg) 
Responders at Wee k 16: 250 mg SC Q4W  (1 injection of 250 mg ) at W20  
Inadequate responders  at Week 16 : 250  mg SC Q2W  (1 injection of 250  mg) 
at W18, W20, and W2 2 
Route of Administration  SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = once every 2 weeks ; Q4W = once 
every 4 weeks ; W = week . 
 
Data Monitoring Committee: No 
 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
12 1.2. Schema   
 
 
Abbreviations: EASI = Eczema Area and Severity Index ; IGA = Investigator’s Global Assessment ; n = number; Q2W = once every 2 weeks; Q4W = once every 
4 weeks; SC = subcutaneous; W = week. 
a Week s 12 and 20 are phone visits . 
b 30-day screening window . 
c Lebrikizumab loading dose of 500  mg SC will be administered at baseline and Week 2.  
d Responders: Participants  who reach IGA 0 or 1 (clear  or almost clear) or a 75% reduction in the EASI score from baseline (EASI -75). Inadequate responders  
are participants  who do not reach these  criteria . 
e The safety follow -up visit will occur approximately [ADDRESS_660813] study intervention  injection.  
 
 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
13 1.3. Schedule of Activities  (SoA)   
  Period I  Period II  Period III  Comments  
 Screening  Baseline  Treatment Period  Post-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660814] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±[ADDRESS_660815] 
dose of study intervention.  
Demographics  X                     Includes  
 ethnicity, sex , and race 
 full date  of birth for participants  12-17 
years of age, and  
 year of birth for participants ≥[ADDRESS_660816] surgical 
and medical history should be collected.  
Prespecified medical 
history (indication and 
history of interest)  X                     Additional data for the indication and 
comorbidities of interest are collected  (including 
conjunctivitis and facial dermatitis) . 
Record  prior treatments 
for indication  X                     Includes medications and therapi[INVESTIGATOR_81177] . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660817]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660818] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±[ADDRESS_660819]  X                     The investigator should review the vaccination 
status of each pediatric participant <18 years of 
age to assess if the participant is up to date with 
immunizations following the local guidelines for 
vaccination with vaccines intended to prevent 
infectious d isease prior to enrolling participants 
into the study.  
For participants who are under -vaccinated, the 
investigator should document the benefit  or risk 
rationale for enrolling the participants in the study.  
Review me narche status  
with date of menarche , if 
applicable  X X X X X   X   X X   For participants <18 years of age.  
If the participant reaches menarche at any time 
during the trial and is sexually active, pregnancy 
testing and contraception requirements will apply . 
See Section 10.4, Appendix 4.  
Concomitant 
medications  X X X X X X X X X X X  
AEs X X X X X X X X X X X Any events that occur after signing the ICF or 
assent are considered AEs as defined in Section 
10.3, Appendix  3. For AESIs, additional data 
could be collected (Section 8.3.3 ). 
Physical Evaluation  
Height  X             X      
Weight  X X      X   X X     
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660820]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660821] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±[ADDRESS_660822] 5 minutes. Use size 
appropriate blood pressure cuff.  
Physical examination  X               X X   The physical exam ination  is performed (excludes 
pelvic  and rectal , unless clinically indicated ). Full 
skin examination is required for BSA calculation.  
Symptom -direct ed 
physical assessment    X X X X   X       X As indicated based on participant status and 
standard of care. May be performed by [CONTACT_447864].  
Participant Diary (Electronic)  
Diary dispensed  X                     Diary includes daily collection of Pruritus NRS, 
Sleep -Loss Scale, and Skin Pain NRS; weekly 
collection of POEM; bi -weekly collection of study 
drug administration information (as applicable).  
TCS usage will be collected daily beginning at V2.  
Pruritus NRS an d Sleep -Loss Scale should be 
completed a minimum of 4  of 7 days before 
baseline.  
Review diary for 
completion of PRO and 
TCS assessments     X X X X X X X X X   For details of these assessments , see Section 8.1. 
Drug administration  
diary compliance check          X X X X X X    
Diary return                  X X     
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660823]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660824] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±7   
Visit Detail            T   T        
PRO s (Electronic)  
Complete prior to any clinical administered assessments   
PO-SCORAD    X         X   X X     
DLQI     X         X   X X   Only for participants >16 years of age at baseline.  
cDLQI    X         X   X X   Only for participants < [ADDRESS_660825]    X    X     X   X X     
Participant -Reported 
Satisfaction  Question             X   X X     
Clinician -Administered Assessments (Electronic)  
IGA  X X X X X   X   X X     
F-IGA    X X  X X    X   X X     
EASI   X X X X X   X   X X     
BSA  X X X X X  X  X X   
PDS   X         X   X X     
Clinician -Administered Assessments (Paper)  
Fitzpatrick Skin Type 
Assessment   X                     
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660826]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660827] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±7   
Visit Detail            T   T        
Participant Education and Supplies  
Participant  or caregiver  
instructions on diary 
completion  X                     Education can also be performed on an as -needed 
basis.  
Remind participant of 
TCS usage restrictions 
and expectations  X                     Required 2 -week wash out of TCS prior to Visit 2. 
See Section s 6.8.1 , 6.8.2 , and 6.8.5  for TCS usage . 
Train partici pant and/or 
caregiver on study 
intervention  
administration       X X               Participants and/or caregivers need to be 
adequately trained on injection technique prior to 
administering injections.  
Training can be done at Week  2 and/or Week [ADDRESS_660828] 
dose of study intervention  for females ≥[ADDRESS_660829] dose of study interve ntion . See 
Section 10.4, Appen dix 4. 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660830]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660831] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±7   
Visit Detail            T   T        
Urine pregnancy (local)    X   X X   X   X X  Collect for WOCBP only. Done locally and prior 
to administering study intervention . Additional 
pregnancy tests , beyond those required per the 
SoA, should be performed at any time during the 
trial if a menstrual period is missed  or there is 
clinical suspi[INVESTIGATOR_51940].  See Section 10.4, 
Appendix 4. 
If required per local regulations and/or institutional 
guidelines, pregnancy testing can occur at other 
times during the study treatment period.  
HIV screening tests  X                       
HCV screening tests   X                     If anti -HCV is positive, it must be followed by a 
HCV RNA test. See Section 8.2.[ADDRESS_660832] an additional unscheduled sample 
as detailed in Section 8.4. 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660833]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660834] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±7   
Visit Detail            T   T        
Immunogenicity (ADA ) 
samples   X  X     X X  Samples to be collected prior to dosing . 
If an immediate or nonimmediate systemic drug 
hypersensitivity reaction occurs, in any participant , 
then also collect an additional unscheduled sample 
as detailed in Section  10.2.1. 
Stored Samples  
Genetics sample    X                   Sample can be obtained at or after the specified 
visit.  
Exploratory biomarker 
samples    X   X     X   X X   Collect prior to dosing . 
Registration  and Dosing  
Register visit with IWRS  X X X X X X X X X X X   
Dispense study 
intervention  via IWRS    X X X X   X           
Administer study 
intervention  in clinic    X X X X   X         Week 0 (Visit 2) and Week 2, dose to be 
administered in the clinic by [CONTACT_3725].  
Weeks 4, 8, and 16 dosing to be performed in 
clinic administered  by [CONTACT_81240].  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660835]-
treatment 
Follow -Up  
Visit Number  1 2 3 4 5 6 7 8 9 ED 801   
Week Relative to Study 
Drug Start  ≤30 (days)  0 2 4 8 12 16 20 24 — [ADDRESS_660836] dose    
Visit Interval Tolerance 
(Days)   — ±3 ±3 ±5 ±5 ±5 ±5 ±5 — ±7   
Visit Detail            T   T        
Dispense study 
intervention  to 
participant for at home 
dosing        X X   X         Injections will be administered by [CONTACT_510913] 6, 10, 12, and 14. 
Responders at Week  16 who will receive Q 4W 
dose will administer study  intervention  at 
Week  20. 
Inadequate  responders at Week  16 who will 
receive Q2W dosing will administer study 
intervention at Weeks  18, 20, and 22. 
Observe participant  or 
caregiver administer 
study intervention  in 
clinic        X                 
Participant returns study 
intervention  and 
injection supplies          X   X   X X   If study intervention  was administered at home by 
[CONTACT_3445], the injection supplies should be saved 
and returned at the next  on-site visit.  
Assess study 
intervention compliance      X  X  X    
Abbreviations: AD = atopic dermatitis ; ADA = anti-drug antibody ; ADCT = atopic dermatitis control tool ; AE = adverse event; AESI = adverse event of special 
interest; BSA = body surface area ; cDLQI  = Children’s Dermatology Life Quality Index ; DLQI = Dermatology Life Quality Index ; DNA = deoxyrib onucleic 
acid; EASI = Eczema Area and Severity Index;  ED = early discontinuation; F-IGA = Face-IGA; HBcAb  = hepatitis B core antibody ; HBsAb = hepatitis B 
surface antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus ; 
ICF = informed consent form ; IGA = investigator global assessment ; IgE = immu noglobulin E; IWRS = interactive web -response system ; NRS = numeric 
rating scale ; PDS = Post-inflammatory Dyschromia Scale ; PO-SCORAD = Patient -Oriented SCORing Atopic Dermatitis ; POEM = Patient -Oriented Eczema 
Measure; PRO = patient -reported outcome; Q2W = once every 2 weeks; Q4W = once every 4 weeks; SoA = schedule of activities; T = telephone ; TCS = 
topi[INVESTIGATOR_11930] ; WOCBP = wome n of child -bearing potential; WPAI -AD =  Work Productivity and Activity Impairment Questionnaire - Atopic 
Dermatitis . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
21 2. Introduction   
Lebriki zumab (LY3650150) is a monoclonal antibody  based on the immunoglobulin G4 ( IgG4 ) 
antibody stabilized by a mutated Fc region. Lebrikizumab binds with high affinity  specifically to 
soluble interleukin ( IL)-13 and blocks IL -13 signaling through the IL-4 receptor alpha ( IL-
4R)/IL-13 receptor alpha 1 ( IL-13R1) pathway, thereby [CONTACT_81243] -13 with high potency . Blockade of IL -13 signaling is expected to be of benefit in 
diseases in which IL -13 is a key contributor to the d isease pathogenesis.  
2.1. Study Rationale   
Atopic dermatitis  (AD)  is a chronic heterogeneous  inflammatory disorder caused by [CONTACT_510914]. In patients  with AD, IL -13, a central 
pathogenic mediator in the disease , is overexpressed, driving multiple aspects of AD 
pathophysiology by [CONTACT_6561] T -helper Type 2 (Th2) cell inflammation and resulting in skin 
barrier dysfunction, itch, infection , and lichenification . There is a paucity of data to guide 
diagnosis and treatment  in populations traditionally under -represented in clinical trials, including 
patients with skin of color  (Price et al. 20 21; Chen et al . 2021) . Compounding th is issue  is the 
complexity of diagnosing moderate -to-severe AD in this patient population , partially due to 
historical lack of representation in medical education resources and in some cases, limited 
exposure to patients with skin of color in medical training  (Ebede et al. 2005 ; Adelekun et al. 
2020;  Ibraheim et al . 2021; Kurtti et al . 2022). Finally , the nuances of identifying erythema in 
patients  with skin of color not only affect the accurate and timely diagnosis of AD but also 
confound the use of AD scales commonly used in clinical trials  (Zhao et al . 2015) . 
Phase [ADDRESS_660837] demonstrated that lebrikizumab is effective in treating participants  with 
moderate -to-severe AD. Subgroup analyses ha ve shown that the efficacy is comparable in 
participants  of African  and Asian  descent ; however , lebrikizumab clinical studies dedicated to 
skin of color participants have  not been conducted to dat e. 
This study aims  to complement  the Phase 3  finding s with a focus on patients with skin of color, 
will include objectives and endpoints commonly evaluated in AD clinical trials, and will 
additionally evaluate novel endpoints , including face -Investigator’s  Global Assessment ( F-IGA), 
Patient -Oriented SCORing Atopic Dermatitis (PO-SCORAD ), Post-inflammatory Dyschromia 
Scale  (PDS) , and AD -related changes in erythema, hypopi[INVESTIGATOR_371] , and hyperpi[INVESTIGATOR_371].  
Data on racial subgroups are generally reported in cl inical trials ; however , the race definition 
may not capture skin of color population appropriately. The results from this study will provide 
important scientific insights in interpreting the clinical response in this rigorously defined skin of 
color popula tion compared to those reported from race -based post hoc subgroup  analyses.  
2.2. Background   
Atopic dermatitis is a complex heterogeneous  disease that is determined by [INVESTIGATOR_18193], 
environmental , and immunologic factors (Werfel et al.  2016; Simon et al. 2019). Genetic studies 
of AD (Bieber 2012; Auriemma et al.  2013; Weidinger et al.  2018) have shown that genes 
encoding for cytokines involved i n the regulation of the immune system (IL-4, IL -5, and IL -13) 
are strongly associated with the development of AD (Novak et al.  2002 ; He et al.  2003; 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
22 Hummelshoj et al. 2003). In addition, variants of genes that encode for proteins involved in skin 
barrier f unction , such as filaggrin (FLG) and loricrin (LOR ), are also associated with AD (Van 
Bever and Llanora 2011).  
Reduced epi[INVESTIGATOR_81183], which represents the first line of protection against the 
environment, is thought to lead to sensitization t o environmental allergens, associated with 
elevated IgE (Werfel et al.  2016) and consistent with the presence in the skin of Type  2 cytokines 
(IL-4, IL -5, IL -9, IL -13, IL -25, IL -31, IL -33, and thymic stromal lymphopoietin ) and 
inflammation. Type 2 cytokine s increase epi[INVESTIGATOR_81184], sensitization, inflammation, and 
pruritus and decrease the expression of antimicrobial pept ides and the barrier proteins FLG, 
LOR, and involucrin. I nterleukin 13 in particular can reduce epi[INVESTIGATOR_510885], LOR, and involucrin (Kim et al. 2008) and can act on 
keratinocytes in the skin to downregulate their differentiation (Howell et al. 2008). I nterleukin 13 
also induces T -cell chemoattractants that mediate T -cell infiltra tion into AD lesions (Purwar et 
al. 2006) and may also induce IL -5 expression and eosinophil infiltration through the induction 
of eosinophil chemoattractants (Esche et al.  2004). Increased expression of IL -13 has 
consistently been reported in AD skin lesi ons and is associated with disease severity (Hamid et 
al. 1996; Jeong et al. 2003; Tazawa et al.  2004 ; La Grutta et al.  2005; Neis et al.  2006; Choy et 
al. 2012; Suárez -Fariñas et al. 2013).  
A Phase 2b , double -blind, placebo -controlled study  of adult  participants with investigator global 
assessment (IGA) (3,4), Eczema Area and Severity Index (EASI ) (≥16), body surface area (BSA ) 
≥10%, chronic AD for at least 1 year, and for whom topi[INVESTIGATOR_510886] t aking lebrikizumab loading dose followed by 250 mg 
subcutaneous  (SC) once every 2 weeks  (Q2W)  met primary endpoint criteria of  EASI least -
squares  mean % change , with % change -72.1, p value <0.00 1, at 16 weeks  (Guttman -Yassky et 
al. 2020). Statistical significance was also reached for the secondary endpoints IGA 0,1 response, 
EASI50, EASI75, EASI90, mean percentage BSA involvement  change from baseline , and 
Pruritus NRS  change from baseline . The top -line results from 2 randomized , controlled , 
monotherapy Phase 3  studies of lebrikizumab (ADvocate 1 and ADvocate  2) and a  third 
completed Phase 3  trial of lebrikizumab in combination with topi[INVESTIGATOR_8826] (ADhere) 
demonstrated positive risk benefit in adult and adolescent patients with moderate -to-severe AD 
at Week 1 6. 
Recruitment and inclusion of patients of color in dermatologic therapy trials, including AD 
studies, is historically limited  (Chen et al . 2022) . The Phase 2 b lebrikizumab study included 16-
28 (30.7% to 35.6%) Black or African American  participants  in each of the 4 arms of the study; 
10% and 21% in pi[INVESTIGATOR_9205] 3  studies  respectively ; these numbers are a significant increase 
compared to historical pharmaceutical dermatologic studies  (Chen et al . 2022) . However, more 
work is needed to fully characterize, support , and treat skin of color populatio ns with AD.  While 
these patient  populations were represented in the clinical  studies, further assessment in the 
context of a focused study and clinical assessments specific to patients of color will generate an 
expanded dataset on the  benefit:  risk balance of lebri kizumab  in this patient group.  
Epi[INVESTIGATOR_510887] a paucity of data describing the prevalence of AD in skin of color populations, with 
ranges of 6%  to 15.89% in Black and/or African American race, 8 % to 9.1% in Asian race, and 
6% in Hispanic ethnicity in the [LOCATION_002]  (US) (Silverberg  and Hanifin 2013). In 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
23 comparison,  the 1-year prevalence of AD among adults in the US is estimated between 2% and 
7% (Harrop et al. 2007 ; Chiesa Fuxench et al . 2018 ; Sacotte and Silverberg 2018 ), and 
approximately 30% of adult patients with AD have moderate -to-severe disease (Bieber and 
Straeter 2015).  
Clinical Manifestations  
Clinically, AD is characterized by [CONTACT_510915] , papules , and/or  plaques  with scale , 
lichenification , and intense pruritus (Bieber 2008), which , along with the distribution, chronicity , 
and history of skin lesions, form the basis for making a diagnosis of AD. Flares  are frequently 
triggered by [CONTACT_81247], irritants, and allergens (Bieber and Novak 2009). 
Several clinical patterns, with differing distributions of skin lesions in distinct age groups  and 
skin types , have been noted ( Weidinger and Novak 2016; Weidinger et al. 2018 ; Sangha  2021 ). 
Classic AD lesions , which are most common in adolescents and adults,  present on the antecubital 
and popliteal fossae. Lesions frequently localize to the face and neck, and a considerable portion 
of patients (around 30%) develop atopic hand dermatitis , which may interfere with workplace 
activities. Lesions may have associated lichenification and crusting, and patients with AD may 
be at increased risk for bacterial cutaneous superinfection.  
Individuals of Afric an descent may be more likely to present with lichenoid papules or profound 
xerosis  (Jungersted et al . 2010, Muizzuddin et al . 2010 ), and erythema may be ma sked by 
[CONTACT_21173][INVESTIGATOR_510888], light brown or ashen gray. Perifollicular accentuatio n, a more 
scattered pattern, and greater extensor involvement are possible. In ad dition, there may be a 
greater burden of post -inflammatory hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_510889]  (Kaufman  et al. 2018 ; Silverberg  et al. 2019 ). Individuals o f Asian descent may have 
AD features clinically consistent with both AD and psoriasis, with more well -demarcated, scaly 
plaques with greater lichenification and perifollicular accentuation  (Noda et al. 2015 ; Kaufman 
et al. 2018 ; Brunner and Guttman -Yassky 2019 ). In contrast, patients of Hispanic ethnicity are at 
higher risk of severe, more recalcitrant AD, and may have greater trunk involvement  (Wei et al. 
2018 ; Silverberg  et al. 2019) . 
Quality of Life 
Patients with AD have a high disease burden , and their quality of life is significantly affected. In 
one study, AD was shown to have a greater negative effect on patient mental health than diabetes 
and hypertension (Zuberbier et al. 2006). Patients with moderate -to-severe AD have a higher 
prevalence  of social dysfunction and sleep impairment, which are directly related to the severity 
of the disease (Williams et al. 2008). Depression, anxiety, and social dysfunction not only affect 
patients with AD but also affect their caregivers (Zuberbier et al. 2006). Compared with 
patients  with psoriasis, patients with AD have lower physical vitality, social functioning, 
emotional, and mental health scores (Kiebert et al. 2002).  There are limited data specifically 
addressing quality of life ( QoL) in patients with  skin of color and AD. A study of  almost 1000 
adults with AD at a US academic center  showed  that more severe health -related QoL impairment 
was observed in Black and Asian patients ( Schwartzman  et al 2022) . More robust data on the 
quality of life for patients with skin of color and moderate -to-severe AD are needed.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
24 Treatment for Atopic Dermatitis  
The therapeutic approach to AD consists primarily of trigger avoidance, skin hydration, and use 
of moisturizers and anti -inflammatory therap ies consisting predominantly of  topi[INVESTIGATOR_030] ( TCS). For patients with deeper skin tones , it is also important to address the need 
for improvement or clearance of post-inflammatory hyperpi[INVESTIGATOR_510890]  
(Davis and Callender  2010) . In many patients, treatment with TCS provides some measure of 
symptomatic relief  but does not always adequately control the disease. In patients with persistent 
moderate -to-severe disease not responding adequately to TCS, the step -up options include 
topi[INVESTIGATOR_22726] , phototherapy  and immunosuppressive agents , such as oral or 
injected corticosteroids, cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil. In 
2017, dupi[INVESTIGATOR_510891] m oderate -to-severe AD , 
and in [ADDRESS_660838] , tralokinumab , was approved for adults with moderate -to-severe 
AD. Also in 2021, the topi[INVESTIGATOR_81191] (JAK) inhibitor ruxolitinib  was approved for the 
treatment of mild-to-moderate  AD in adults and children aged [ADDRESS_660839] potential  side effects , and 
may require intensive lab monitoring ; the JAKs , upadacitinib and abrocitinib , have a safety 
signal that may not be appealing for many patients and providers and are therefore commonly 
not chosen as first -line therapy, and although dupi[INVESTIGATOR_510892], specific studies on skin of color populations have not been completed, signaling a 
clinical care gap  (Seegräber  et al 2018; Gooderham  et al 2018) . This study will fill this clinical 
gap by [CONTACT_510916] d AD outcomes characterization of novel endpoints that are 
important for individuals with skin of color.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of lebrikizumab is 
provided in the Investigator’s Brochure  (IB). 
2.3. Benefit/Risk Assessment   
As of [ADDRESS_660840] received 
lebrikizumab. Lebrikizumab has been given to 525 healthy people and 5849 study participants 
with AD, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and 
Hodgkin’s lymphoma. Approximately [ADDRESS_660841]  been treated with lebrikizumab in the Phase 2  
and Phase 3  AD program s. 
The use of lebrikizumab for the treatment of AD is supported by [CONTACT_81249] -13 in skin. Moreover, 
Phase 2 efficacy studies of lebrikizumab ( J2T-DM-KGAG/TREBLE , J2T -DM-KGAH/ARBAN , 
and J2T -DM-KGAF/DRM06 -AD01) demonstrated significant clinical benefit in participants 
with AD. The top -line results  from the 2 monotherapy  Phase 3  studies of lebrikizumab  
(ADvocate 1 and ADvocate 2)  achieve d the primary and all key secondary endpoints, including 
skin clearance and itch improvement  at Week [ADDRESS_660842] completed pi[INVESTIGATOR_9205] 3 trial of 
lebrikizumab in combination with topi[INVESTIGATOR_8826] (ADhere) also met all primary and key 
secondary endpoints at Week 16 . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
25 Potential risks associated with lebrikizumab include conjunctivitis, eosinophilia and eosinophilic 
conditions, herpes zoster and herpes infections (Section 8.3.3 ), anaphylaxis and hypersensitivity 
reactions  (Section 8.3.5 ), and other infections  (Section [IP_ADDRESS] ). 
In the initial 16 -week , placebo -controlled period of ADvocate 1 and ADvocate 2, the incidence 
of treatment -emergent adverse events ( TEAEs) and serious adverse event (SAEs) among patients 
treated with lebrikizumab was consistent with that of the previous Phase [ADDRESS_660843] common AEs included conjunctivitis, nasopharyngitis , and headache for 
lebrikizumab -treated patients. Discontinuations due to AEs were similar in the lebrikizumab 
group (1.4%) compared to placebo (1.7%). The safety profile of lebrikizuma b observed in the [ADDRESS_660844] trial -level safety reviews at periodic intervals throughout the study.  
In summary, in the context of the cumulative knowledge for lebrikizumab, the benefit/risk 
balance is assessed to be acceptable for testing in this Phase 3b study.  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of lebrikizumab  may be found in the IB or Development Safety Update 
Report.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
26 3. Objectives , Endpoints , and Estimands   
Objectives  Endpoints  
Primary   
 To assess the effect of  lebrikizumab 
250 mg Q2W in reduc ing the  signs 
and symptoms of AD in participants 
with moderate -to-severe AD  and skin 
of color   Percentage of participants  achieving EASI -75 
(≥75% reduction from baseline in EASI) at 
Week 16  
Secondary   
 To evaluate the effect of treatment 
with lebrikizumab in  the signs and 
symptoms of AD and health outcome 
measures, in participants with 
moderate -to-severe AD  and skin of 
color   Percentage of pa rticipants  achieving EASI -75 at 
Week 24  
 Percentage of participants  with an IGA score of 
0 or 1 and a reduction ≥2 points from baseline to 
Week s 16 and 24  
 Percentage  change in EASI total from baseline 
to Week s 16 and 24  
 Change in EASI total from baseline to Week s 16 
and 24  
 Percentage  of participants  achieving EASI 90 at 
Week s 16 and 24  
 Percentage of p articipants  with a Pruritus NRS 
of ≥4  points at baseline who achieve a 4 -point 
reduction at Week s 16 and 24  
 Percentage of pa rticipants with a Pruritus NRS 
≥[ADDRESS_660845] 3 -
point reduction at Week s 16 and 24  
 Percentage change in Pruritus NRS score from 
baseline to Week s 16 and 24  
 Percentage of p articipants  with a Sleep -Loss 
Scale score of ≥2  points at baseline who achieve 
a 2-point reduction at Week s 16 and 24  
 Percentage change in Sleep -Loss Scale score 
from baseline to Week s 16 and 24  
 Percentage of pa rticipants  with a Skin Pain NRS 
of ≥4  points at baseline who achieve a 4 -point 
reduction from  baseline  to Week s 16 and 24  
 Change in POEM from baseline to Week s 16 
and 24  
 Change in DLQI from baseline to Week s 16 and 
24 for participants ≥16 years of age at baseline  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
27  Change in cDLQI from baseline to Week s 16 
and 24  for participants <16 years of age at  
baseline  
 Percentage of pa rticipants  with a DLQI of 
≥4 points at baseline who achiev e a ≥4-point 
improvement in DLQI at Week s 16 and 24  for 
participants ≥16 years of age at baseline  
Exploratory   
 To evaluate the efficacy and health 
outcome measures of lebrikizumab 
from baseline by [CONTACT_510917] -to-severe AD   Percentage change in PO-SCORAD from 
baseline by [CONTACT_765]  
 Change in Post-inflammatory Dyschromia Scale  
from baseline by [CONTACT_765]  
 Percentage change in  ADCT  from baseline by 
[CONTACT_765] 
 Using WPAI -AD by [CONTACT_765] , change in baseline in  
o absenteeism  in those who are currently 
employed (working for pay) 
o presenteeism  in those who are currently 
employed (working for pay)  
o overall work impairment  in those who 
are currently employed (working for 
pay), and 
o impairment in activities  (all 
participants ) 
 Percentage of participants  with an F-IGA score 
of 0 or 1 and a reduction ≥2 points from baseline 
by [CONTACT_765]  
 Lichenification change from baseline (calculated 
from EASI)  
 Participant  satisfaction  change from baseline  (1 
question)  
 Percentage of pa rticipants  achieving EASI -75 by 
[CONTACT_765] 
 Percentage of participants  with an IGA score of 
0 or 1 and a reduction ≥2 points from baseline 
by [CONTACT_765] 
 Percentage  change in EASI total by [CONTACT_765]  
 Change in EASI total by [CONTACT_765]  
 Percentage  of participants  achieving EASI -90 by 
[CONTACT_510918] 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
28  Percentage of p articipants  with a Pruritus NRS 
of ≥4  points at baseline who achieve a 4 -point 
reduction by [CONTACT_765]  
 Percentage of participants with a Pruritus NRS 
of ≥3 points at baseline who achieve a 3 -point 
reduction by [CONTACT_765]  
 Percentage change in Pruritus NRS score by 
[CONTACT_765] 
 Percentage of p articipants  with a Sleep -Loss 
Scale score of ≥2  points at baseline who achieve 
a 2-point r eduction by [CONTACT_765]  
 Percentage change in Sleep -Loss Scale score 
from baseline by [CONTACT_765]  
 Percentage of pa rticipants  with a Skin Pain NRS 
of ≥4  points at baseline who achieve a 4 -point 
reduction from baseline  by [CONTACT_765]  
 Change from baseline in POEM by [CONTACT_765]  
 To discern  respon der variability 
within the study  and to track 
response variability to lebrikizumab   Changes from baseline in serum proteins related 
to AD pathogenesis : Refer to Appendix 2  
Abbreviations: AD = atopic dermatitis; ADCT  = atopic dermatitis cont rol tool ; cDLQI = Children ’s DLQI ; DLQI = 
Dermatology Life Quality Index ; EASI = Eczema Area and Severity Index ; F-IGA = face -IGA; IGA = 
Investigator’s Global Assessment ; NRS = numeric rating scale; PDS = Post-inflammatory Dyschromia Scale ; 
POEM = Patient -Oriented Eczema Measure ; PO-SCORAD = Patient -Oriented SCORing Atopic Dermatitis ; Q2W = 
once every 2 weeks; WPAI -AD = Work Productivity and Activity Impairment Questionnaire –Atopic Dermatitis . 
 NOTE: Endpoints in the table above collected by [CONTACT_81238].  
Primary estimand  
The primary clinical question of interest is: What is the intervention effect in percentage of 
participants achieving at least 75% improvement from baseline in  EASI -75 after 16 weeks of 
lebrikizumab 250 mg Q2W intervention in participants with skin of color and moderate -to-severe 
AD who remain on study treatment until Week 16 . 
The estimand is described by [CONTACT_6570]:  
Population: participants with skin of color and moderate -to-severe AD  who met inclusion and 
exclusion criteria  and who remain ed on study treatment until Week 16 . Further details can be 
found in Section 5. 
Endpoint: whether participants achiev e at least 75% improvement from baseline in EASI  at 
Week 16 . 
Intercurrent events : There are no intercurrent events for this population since participants who 
initiate rescue medication are discontinued from the study and hence study treatment. Therefore, 
participants who stay on study treatment through Week [ADDRESS_660846] an intercurr ent event 
such as initiating rescue medication or permanently discontinuing treatment . Further details on 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
29 study interventions and concomitant medications, including rescue treatments , can be found in 
Section 6.8.1 . 
Population -level summary: percentage of participants achieving EASI  75 response  at Week 16.  
 
Secondary estimand(s)  
There is no secondary estimand planed at this stage ; however, additional estimand s might be 
specified in the statistical analysis plan ( SAP). 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
30 4. Study Design   
4.1. Overall  Design   
Study J2T-MC-KGBP ( KGBP ) is a single group treatment , open -label , Phase 3b  study , which is 
24 weeks in treatment duration. The study is designed to evaluate the safety and efficacy of 
lebrikizumab in adolescent and adult participants with skin of color and  moderate -to-severe AD.  
Study Periods  
This trial has 3 study periods:  
 Screening (Visit 1: ≤ 30 days prior to baseline ) 
 Treatment (Visits 2 -9: 24 weeks)  
 Safety follow -up (Visit 801: approximately [ADDRESS_660847] treatment)  
Visit Types  
Study visits at Week 12 (Visit 6) and Week 20 (Visit 8) will be performed virtually , that is , via 
telephone or telemedicine tools . 
All other visits will be conducted at the clinical trial site.  
Dosing  
During the 24-week Treatment  Period, approximately  95 participants  will receive treatment : 
 500 mg subcutaneous (SC) once every 2 weeks  (Q2W ) loading dose at baseline and 
Week 2, followed by 250  mg SC Q2W  until Week 16 . 
 Responders, defined as achieving IGA (0,1) or EASI -75 at Week 16, will receive 
250 mg SC Q 4W. 
 Inadequate responders at Week 16 will continue to receive 250 mg SC Q2W . 
The study population is described in Section 5. 
The e fficacy and safety assessments  are described in Sections 8.1 and 8.2, respectively . 
4.2. Scientific Rationale for Study Design   
There is a paucity of data to guide diagnosis an d treatment in populations traditionally under -
represented in clinical trials, including patients with skin of color.  The present study will 
evaluate the safety and efficacy of the skin of color population with clinical assessment methods 
suitable for this population  to complement the already exi sting data on racial subgroups from the 
lebrikizumab clinical programs. Clinical studies (Phase 2a Study GS29250 and Phase 2b Study 
DRM06 AD01) with lebrikizumab demonstrated significant clinical benefit in participants with 
AD. Additional detail ed discussion of the lebrikizumab studies is provided in the lebrikizumab 
IB. The top -line results from 2 randomized controlled monotherapy Phase 3  studies of 
lebrikizumab (ADvocate 1 and A dvocate  2) and a  third completed Phase 3  trial of lebrikizumab 
in combination with topi[INVESTIGATOR_8826] (ADhere) demonstrated  positive risk benefit in adult and 
adolescent patients with moderate -to-severe AD  at Week 1 6. Additional detailed discussion of 
the lebrikizumab studies is provided in the lebrikizumab IB.  Since randomized controlled data 
are already available , this study will be conducted as an open -label study to mimic the real -world  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660848] Week 1 6. 
In this study, collection of demographic information includes race and ethnicity. The scientific 
rationale is based on the need to assess variable response in safety and efficacy based on race or 
ethnicity. This question can be answered only if all the relevant data are collected . 
4.2.1.  Participant Input into Design   
Throughout this protocol, the term “participant” is used to indicate an individual who participates  
in a clinical trial, either as a recipi[INVESTIGATOR_510893] a control. This usage  
reflects preferences indicated by [CONTACT_510919].  
 
No participant input was provided for this study design.  
4.3. Justification for Dose   
The lebrikizumab dosing regimen of 500  mg loading dose at baseline and Week 2, foll owed by 
250 mg Q2W up to, and including Week 16, was selected based on an evaluation of safety, 
efficacy, and PK data from the Phase 2 and Phase 3 lebrikizumab trials.  
In the lebrikizumab Phase 3 programs, IGA 0/[ADDRESS_660849] Week 16 are based on the results of these Phase 3 
studies.  
Adolescent Participants  
In this Phase 3b study, adolescent p articipants (≥12 to <18 years weighing ≥40  kg) will be 
included and will receive the same doses of lebrikizumab as adult participants. Pharmacokinetic 
analyses of SC doses of lebrikizumab reveal similar kinetics for adults and adolescents ≥12 to 
<[ADDRESS_660850] ed that the 
adolescent AD participants ≥[ADDRESS_660851] participant in the study . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
32 5. Study Population   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant s must be ≥12 years of age inclusive, at the time of signing the informed 
consent/assent . 
Type of Participant and Disease Characteristics  
2. Participants who are self -reported race other than White, including but not limited to 
persons who self -identify as Black or African American, American Indian or A laska 
Native, Asian, Native Hawaiian , or Other Pacific Islander.  
3. Participants who are Fitzpatrick phototype IV -VI (Section 8.1.15 ). 
4. Have chronic AD (according to American Academy of Dermatology Consensus Criteria; 
Eichenfield et al. 2014; Appendix 7, Section 10.7) that has been present for ≥[ADDRESS_660852] EASI ≥[ADDRESS_660853] Investigator’s Global Assessment ( IGA) score ≥3 (scale of 0 to 4) at the baseline 
visit. 
7. Have ≥10% BSA of AD involvement at the baseline visit . 
8. Have a history  of inadequate response to treatment with topi[INVESTIGATOR_5910]; or 
determination that topi[INVESTIGATOR_12432] . 
Weight  
9. For adolescent participants, b ody weight ≥40 kg at baseline . 
Sex and Contraceptive/Barrier Requirements  
10.  Male and/or female  
a. No male contraception is required except in compliance with specific local 
government study requirements.  
b. Female participants of child -bearing  potential must agree to remain  abstinent 
(refrain from heterosexual intercourse) or use a highly effective contraceptive 
method during the treatment period and for at least [ADDRESS_660854] dose of 
study drug. Women not of child -bearing  potential ( WNOCBP ) may participate 
without any contraception requirements. For definitions of women of child -
bearing  potential (WOCBP) and WNOCBP , see Section 10.4, Appendix 4. 
Cont raceptive use by [CONTACT_61511].  For the contraception 
requirements of this protocol, see Section 10.4, Appendix  4. 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
33 Informed  Consent  
11. Informed consent/ assent  
a. For adult participants : capable of giving signed informed consent as described in 
Appendix 1 , which includes compliance with the requirements and restrictions 
listed in the ICF and in this protocol . 
b. For adolescent participants: a parent or legal guardian must be able to read, 
understand, and give documented informed consent for a chi ld to participate in 
this study as described in Section 10.1.3 , which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol . 
NOTE: Adolescents reaching the age of majority while on study must provide 
consent to continue participation in the study . 
Other  
12. Are willing and able to comply with all clinic  visits and study -related procedures and 
questionnaires.  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
13. History of human immunodeficiency virus (HIV) infection or po sitive HIV serology at 
screening.  
14. Have a current infection  or chronic infection with hepatitis B virus (HBV ) at screening , 
that is, positive for hepatitis B surface antigen (HBsAg ) and/or polymerase chain reaction  
positive for HBV DNA (Section 8.2.3 ). 
15. Have a current infection with hepatitis C virus (HCV ) at screening , that is, positive for 
HCV RNA (Section 8.2.4 ). 
16. Have an uncontrolled chronic disease that might require multiple intermittent uses of oral 
corticosteroids  at screening  (as defined by [CONTACT_093]).  
17. Have uncontrolled asthma that  
a. might require bursts of oral  or systemic corticosteroids, or  
b. required the following due to ≥1 exacerbations within 12 months before baseline  
i. systemic (oral and/or parenteral) corticosteroid treatment, or  
ii. hospi[INVESTIGATOR_272] >[ADDRESS_660855] known liver cirrhosis and/or chronic hepatitis of any etiology.  
19. History of malignancy, including mycosis fungoides  or cutaneous T-cell lymphoma , 
within [ADDRESS_660856] ed history of immunosuppression, including history of invasive 
opportunistic infections (e.g., tuberculosis, histoplasmosis, listeriosis, 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
34 coccidioidomycosis, pneumocystosis, and aspergillosis) despi[INVESTIGATOR_12468]; or 
unusually frequent, recurrent,  or prolonged infections, per the investigator ’s judgment . 
22. Have presence of skin comorbidities that may interfere with study assessments . 
23. Have a severe concomitant illness(es) that in the investigator’s judgment  would adversely 
affect the participant ’s participation in the study.  
24. Have any other medical or psychological condition that in the opi[INVESTIGATOR_81204] a new and/or insufficiently understood disease, may present an unreasonable 
risk to the study participant because of his/her p articipation in this clinical trial, may 
make participant ’s participation unreliable, or may interfere with study assessments.  
25. Have had any of the following types of infection within 3 months of screening or develop 
any of these infections during screening : 
a. Serious (requiring hospi[INVESTIGATOR_059], and/or intravenous or equivalent oral antibiotic  
treatment)  
b. Opportunistic (as defined in Winthrop et al. 2015 , see Section 10.9, Appendix 9) 
NOTE: Herpes zoster is considered active and ongoing until all vesicles are dry 
and crusted over.  
c. Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer)  
d. Recurring (including, but not limited to recurring  cellulitis, chronic osteomyelitis)  
NOTE: Participants with only recurrent, mild , and uncomplicated orolabial and/or 
genital  herpes may be discussed with the sponsor’s medical monitor to determine 
whether the  participants meet this exclusion criterion.  
26. Have  an active or acute infection requiring treatment with systemic antibiotics,  antivirals, 
antiparasitics, antiproto zoals, or antifungals within 2 weeks before the baseline  visit 
(baseline ; Visit 2), or superficial skin infections within 1 week before the  baseline visit.  
NOTE:  
Participants may be rescreened after infections resolves . 
Participants who have an upper respi[INVESTIGATOR_4416], a vaginal candida infection, 
or an oral candida infection and who are being treated only symptomatically and 
not requiring systemic anti -infectives may be considered for enrollment if other 
study eligibility criteria are met. Enrollment of participants with other 
uncomplicated local infections should be discussed with the sponsor’s designated 
medical monitor.  
Prior/Concomitant Therapy  
27. Prior treatment with tralokinumab.  
28. Prior treatment with dupi[INVESTIGATOR_12458].  
29. Treatment with topi[INVESTIGATOR_12450]: corticosteroids, calcineurin inhibitors, JAK inhibitors , or 
phosphodiesterase -4 inhibitors , such as crisaborole within 2 week s prior to baseline visit . 
30. Treatment with any of the following agents within 4 weeks prior to the baseline visit:  
a. systemic immunosuppressive  or immunomodulating drugs (e.g., systemic 
corticosteroids, cyclosporine, mycophenolate  mofetil, IFN -gamma , azathioprine, 
methotrexate, and other immunosuppressants ) 
b. small molecules (e.g. JAK inhibitors)  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660857] regularly used (more than 2 visits per week) a tanning booth or parlor within 4 
weeks  of the screening visit (Visit 1).  
32. Are currently receiving build -up dosing of allergen immunotherapy (allergy shots).  
33. Treatment with B-cell-depleting biologics, including rituximab, within [ADDRESS_660858] dose of study intervention.  
NOTE : The following are not considered live vaccines: RNA vaccines, vaccines with 
inactive viral elements, and/or nonreplicating viral vector vaccines.  
36. Have received a  Bacillus Calmette -Guerin  (BCG ) vaccination or treatment within less 
than 4 weeks before the baseline visit , or intend to receive BCG vaccination or treatment 
during the study.  
37. Use of cannabis or cannabinoids for the treatment of pruritus, pain, and /or AD. 
Diagnostic Assessments  
38. In the opi[INVESTIGATOR_871], have any clinically significant l aboratory results from 
the chemistry  or hematology tests obtained at the screening visit  (Visit 1) . 
Prior/Concurrent Clinical Study Experience  
39. Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study . 
40. Treatment with an investigational drug within 8 weeks or within 5 half -lives (if known), 
whichever is longer  prior to the baseline visit . 
41. Have received a dose of lebr ikizumab in any prior lebrikizumab clinical study.  
Other Exclusions  
42. Are Lilly employees , or are employees of any third -party involved in study who require 
exclusion of their employees . 
43. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted . 
44. Are pregnant  or breastfeeding  or are planning  to become pregnant or to breastfeed during 
the study . 
45. Have a known hyp ersensitivity to any component of lebrikizumab.  
46. Participant  or caregiver  who is unwilling to administer SC injections of study medication . 
5.3. Lifestyle Considerations   
Not applicable.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
36 5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials  publishing requirements and to respond to queries from regulatory authorities. 
Minim al information includes demography, screen failure details, eligibility criteria, and any 
SAE . 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened  as defined below . Rescreened participants should be assigned a new participant 
number for every screening  or rescreening event.  
5.4.1.  Rescreening for Individuals Who Failed Screening   
Informed consent for rescreenings  
Individuals who are  to be rescreened must first sign a new ICF (Appendix 10, Section 10.1.3 ). 
Such individuals will be assigned a new participant number.  
Rescreening after failure to m eet study entry criteria  
An individual who does not meet the criteria for participation in this study for any reason may be 
rescreened one time . 
When rescreening, all of the screening tests and procedures should be repeated.  
5.5. Criteria for Tempo rarily Delaying Enrollment/Administration of 
Study Intervention of a Participant   
Not applicable.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
37 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  
6.1. Study Intervention(s) Administered   
Lebrikizumab  drug product  is provided as sterile liquid s and contain no preservatives.  
Intervention Name  [CONTACT_81294]  250 mg (125 mg/mL), 2  mL Solution  
Dosage Level  Loading Dose:  
Week 0 : 500 mg ( 2 injections  of 250 mg) 
Week 2 : 500 mg ( 2 injections  of 250  mg) 
 
Post-loading Dose :  
Weeks 4 -16: 250 mg SC Q2W  (1 injection  of 250  mg) 
Responders at Week 16 : 250 mg SC Q4W (1 injection of 250 mg)  at W20  
Inadequate responders  at Week 16 : 250 mg SC Q2W (1 injection of 250  mg) 
at W18, W20, and W2 2 
Route of Administration  SC 
Abbreviations: mg = milligram; mL = milliliter; SC = subcutaneously; Q2W = once every 2 weeks ; Q4W = once  
every 4 weeks ; W = week . 
 
6.1.1.  Medical Devices   
1. Lebrikizumab will be administered using a sterile prefilled syringe with needle safety 
device . Each prefilled syringe is intended for a single 2  mL dose (250  mg) administered 
subcutaneously device . 
2. Instructions on how to use the device  will be provided.  
3. All PCs, including malfunction, use error , and inadequate label ing, shall be documented 
and reported by [CONTACT_107873] (see Section  8.2.2 ) 
and appropriately managed by [CONTACT_456].  
6.2. Preparation , Handling , Storage , and Accountability   
1. The investigator or designee must confirm appropriate storage  conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention . Only authorized 
study personnel  may supply , prepare,  or administer study intervention , except  for study 
intervention intended to be administered by [CONTACT_448857].  All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
38 (manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
3. The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and 
final disposition records).  
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Study Reference Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding   
In this open -label study , potential bias will be reduced by [CONTACT_510920] . Adherence to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct . 
The site will contact [CONTACT_81254] -response system  (IWRS ), prior to the start of study 
intervention administration and at the primary endpoint for each eligible participant , to provide  
demographic information  and IGA/EASI  results , respectively . 
6.4. Study Intervention Compliance   
Study intervention will be administered under medical supervision by [CONTACT_81255] (Week 0, Visit 2) and Week 2 (Visit 3) visits . The dose of study 
intervention and study participant identification will be confirmed prior to dispensing study drug . 
The date and time of each dose administered will be recorded in the source do cuments and will 
be provided to the sponsor as requested . 
Beginning Week 4 (Visit 4), the participant/ caregiver will be encouraged to administer the study 
intervention while in the clinic  or at home . Participants may choose to continue to receive study 
drug injections administered by [CONTACT_81256]. Home 
dosing must be self -administered or given by a caregiver that has received proper injection 
technique training.  
When participants self -administer study interventi on(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by [CONTACT_81257] , 
counting returned injection supplies  and documented in the source documents.  
A record of the number of lebrikizumab  injections supplies  dispensed to and administered  by 
[CONTACT_510921].  
6.5. Dose Modification   
Dose modifications of lebrikizumab are not allowed in this study  
6.6. Continued Access to Study Intervention after the End of the Study   
Lebrikizumab will be made available to el igible participants who complete Visit 9 (Week 24)  via 
the Continued Access addendum, until lebrikizumab is commercially available in the US . Please 
refer to KGB P Protocol Addendum 3 for additional information. Otherwise, lebrikizumab will 
not be provided after participants exit this study.   
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
39 6.7. Treatment of Overdose   
For this study, any dose of lebrikizumab  greater than 500 mg (baseline and Week 2) and 250  mg 
Q2W  (Week 4 and beyond)  will be considered an overdose.  
Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the investigator/treating physician should:  
● Contact [CONTACT_10990].  
● Evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupted or whether the dose should be 
reduced.  
● Closely monitor the participant for any AE/SAE and laboratory abnormalities 
until lebrikizumab can no longer be detected systemically (at least 18 weeks ). 
6.8. Concomitant Therapy   
Any medication or vaccine , including over -the-counter or prescription medicines, vitamins, 
antacids , and/or herbal supplements , that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with  
● reason for use  
● dates of administr ation including start and end dates , and  
● dosage information including dose and frequency for concomitant therapy of 
special interest . 
The medical monitor should be contact[CONTACT_510922].  
Participants should be instructed to consult with the investigator prior to initiating any new 
medication (either self -administered non -prescription drugs or prescription therapy prescribed by 
[CONTACT_20427]) whil e participating in the study. The investigator is expected to examine the 
acceptability of all concomitant medications, topi[INVESTIGATOR_12469], and dietary supplements taken 
by [CONTACT_81260].  
The use of any concomitant medication must relate to a n AE listed on the AE case report form  
(CRF ) or the participant’s medical history, unless the medication is a supplement or used as 
preventive care . 
6.8.1.  Permitted Treatments and Procedures   
The following therapi[INVESTIGATOR_81206]:  
Permitted Concomitant Medications and 
Vaccines  Comments  
Medications   
Medications for medical conditions other than 
AD, e.g., hypertension  and diabetes   
Low and/or mid-potency  TCS, TCIs (e.g., 
tacrolimus and pi[INVESTIGATOR_031]), or topi[INVESTIGATOR_22732] -[ADDRESS_660859] 
be documented in the diary . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
40 Permitted Concomitant Medications and 
Vaccines  Comments  
inhibitors (e.g., crisaborole)  for treatment of 
AD 
High -potency TCS  for treatment of AD  Permitted up to 10 days  
Non-medicated moisturizers   
Intranasal corticosteroids   
Inhaled corticosteroids and bronchodilators to 
control asthma   
Single intra -articular (bursa, tendons, and 
ligaments) corticosteroid injection   
Non-sedating antihistamines   
Ophthalmic drugs containing antihistamines, 
corticosteroids, or other immunosuppressants   
Allergen immunotherapi[INVESTIGATOR_510894] . 
Leukotriene inhibitors   
Systemic and topi[INVESTIGATOR_900] -infectives  For treatment of acute infections.  
Sedating systemic antihistamines including, but 
not limited to, alimemazine, chlorphenamine, 
clemastine, cyproheptadine, diphenhydramine, 
hydroxyzine, ketotifen, and promethazine  On an as -needed basis.  
Systemic  or oral sleep aid medications  On an as -needed basis.  
Recreational use of cannabis and cannabinoid  Not allowed for the treatment of pruritus, 
pain and/or AD  
Vaccines   
Non-live vaccinations  Including non -live SARS -CoV -2 vaccines, 
RNA vaccines, vaccines with inactive viral 
elements, and/or non -replicating viral 
vectors that are clinically indicated.  
Abbreviations: AD = atopic dermatitis; PDE -4 = phosphodiesterase -4; RNA = Ribonucleic acid ; SARS -CoV -2 = 
severe acute respi[INVESTIGATOR_6507] 2 ; TCI = topi[INVESTIGATOR_22726] ; TCS =  topi[INVESTIGATOR_030] . 
NOTE:  in the context of this table, “during the study” = from screening to post-treatment safety follow -up 
visit.  
6.8.2.  Prohibited Treatments and Procedures   
The following therapi[INVESTIGATOR_81208]:  
Prohibited  Concomitant Medications, 
Vaccinations, and Procedures  Comments  
Medications or procedures   
Systemic corticosteroids (IM, PO, or IV)  NOTE: If used for treatment of AEs, it will 
be considered as rescue medication (see 
Section 6.8.5 ). 
Any investigational drug other than the study 
drug  
B cell -depleting biologics, including rituximab   
Other b iologic agents  (other than the study 
interventions)   
Topi[INVESTIGATOR_510895] (see Section 6.8.5 ) 
TCS (high potency)  Use for >10 days  is prohibited  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660860] AD (e.g., immunosuppressive  or 
immunomodulating drugs , such as systemic 
corticosteroids, mycophenolate  mofetil, IFN -γ, JAK 
inhibitors, cyclosporine, azathioprine, or methotrexate; 
phototherapy or PUVA; or systemic PDE -4 inhibitors)   
Systemic and topi[INVESTIGATOR_900] -infectives  For chronic treatment during the study . 
Planned or anticipated major medical 
procedures or surgeries   
Tanning booth  or parlor   
Bleach bath   
Use of cannabis or cannabinoids for the 
treatment of pruritus, pain , and/or AD   
Vaccines   
Live or live attenuated vaccines, as well as 
BCG vaccine   
Abbreviations : AD = atopic dermatitis; AE = adverse event; BCG = Bacillus Calmette -Guerin; IFN-γ = interferon -
gamma;  IM = intramuscular; IV = intravenous; JAK = Janus kinase; PDE 4  = phosphodiesterase -4; PUVA = 
photochemotherapy ; TCS = topi[INVESTIGATOR_11930] ; PO = by [CONTACT_1966] . 
NOTE:  in the context of this table, “during the study” = from screening to post-treatment safety follow -up 
visit.  
6.8.3.  Non-Medicated Moi sturizer s  
Participants may apply a stable dose of non -medicated topi[INVESTIGATOR_81210] 
≥[ADDRESS_660861], then topi[INVESTIGATOR_81211] -potency treatment  if needed. In sensitive 
skin areas , i.e., face, neck, intertriginous, and genital areas, only low -potency topi[INVESTIGATOR_510896].  
If AD lesions recur or a participant experiences a flare, as needed use of low - and/or mid -
potency TCS, TCI (tacrolimus or pi[INVESTIGATOR_031]), and/or topi[INVESTIGATOR_22732]4 inhibitors (crisaborole) 
may be initiated at the participant’s discretion but must be communicated to the investigator and 
documented in the patient diary or as conco mitant medications.  . Escalation to high -potency 
topi[INVESTIGATOR_510897] 7 days of low - or mid-potency TCS, TCI , and/or topi[INVESTIGATOR_22732]4 
inhibitors .(Section  6.8.5 ). Use of high -potency TCS for more than 10 days is considered rescue 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660862] be discontinued from the study ( see 
Section 7.1). All topi[INVESTIGATOR_510898] . 
6.8.5.  Rescue Medicine for Atopic Dermatitis   
The goal of this Phase 3 b study is to demonstrate the safety  and effic acy of lebrikizumab for 
moderate -to-severe  AD in participants with skin of color . To be consistent with real world  
practice,  defined topi[INVESTIGATOR_510899] (see Section 6.8.4 ). Rescue 
therapi[INVESTIGATOR_510900].  Escalation to high -potency topi[INVESTIGATOR_81216], topi[INVESTIGATOR_81218], phototherapy , and/or systemic 
medications , including but not limited to corticosteroids, immunosuppressants, biologics, small 
molecules, etc ., for the treatment of AD should only occur if participants do not respond 
adequately after at least 7 days of low - or mid-potency TCS, TCI , and/or topi[INVESTIGATOR_22732]4 
inhibitors . Any use of topi[INVESTIGATOR_81218], phototherapy, and/or systemic medications will be 
considered Rescue Therapy.  Use of high -potency TCS for more than [ADDRESS_660863]  be discontinued from the study 
(see Section 7.1). All rescue medication must be recorded  in the CRF.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
43 7. Discontinuation of Study Intervention and Part icipant 
Discontinuation/Withdrawal   
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1.  
7.1. Discontinuation of Study Intervention   
When  necessary , a participant  may be permanently discontinue d from  study intervention . If so, 
the pa rticipant  will remain in the study to complete procedures for an early discontinuation visit 
and post-treatment follow -up, if applicable , as shown in the SoA . 
A participant should be permanently discontinued  from study intervention if  
 the participant becomes pregnant du ring the study  
 in the opi[INVESTIGATOR_871], the participant should permanently discontinue the 
study intervention for safety reasons  
 the participant develops a malignancy , except for successfully treated basal or 
squamous cell skin carcinoma  
 the participant tests positive for HBV DNA (see Section 8.2.3 ) 
 the participant  tests positive for HCV  RNA (Section 8.2.4 ) 
 if the participant experi ences a hepatic event or liver test abnormality as specified in 
the liver chemistry stoppi[INVESTIGATOR_3418]  (see Section 7.1.1 ) 
 the participant develops HIV infection  
 the participant develops any  infection that is opportunistic, such as active tuberculosis  
and other infections  whose nature or course may suggest an immuno -compromised 
status  
 the participant requires rescue medication treatment for symptoms of AD in the 
treatment period , and  
 the participant has an AE or an SAE or a clinically significant change in a laboratory 
value  that, in the opi[INVESTIGATOR_871], merits discontinuation of study 
intervention  and appropriate measures being taken.  
Hepatitis  
 prior to discontinuation of any immunomodulatory and/or immunosuppressive 
therapy  due to hepatitis , including study inte rvention, the participant is to be referred 
to, evaluated, and managed by a specialist physician with expertise in evaluation and 
management of viral hepatitis.  
 the timing of discontinuation from study intervention relative to the initiation of any 
antivir al treatment for hepatitis is to be based on the recommendation of the 
consulting specialist physician, in conjunction with the investigator, and aligned with 
medical guidelines and standard of care.  
Hypersensitivity  
 if the investigator determines that a s ystemic hypersensitivity reaction has occurred 
related to study intervention administration, the participant may be permanently 
discontinued from the study intervention, and the sponsor’s designated medical 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
44 monitor should be notified. If the investigator i s uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of study 
intervention is warranted, the investigator may consult the sponsor . 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_510901] (see Section 8.2.2 ) if 
1 or more of these conditions occur:  
Elevationa Exceptiona 
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_660864] >3x ULN and either TBL >2x ULN or 
INR >1.5  For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL  >2x 
ULN.  
ALT or AST >3x ULN with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain 
or tenderness, fever, and/or  rash  
ALP >3x ULN, when the source of increased ALP is 
the liver   
ALP >2.5x ULN and TBL >2x ULN  For participants with Gilbert’s 
syndrome: If baseline direct 
bilirubin is >0.5 mg/dL, then 
doubling of direct bilirubin should 
be used for drug interruption 
decisions rather than TBL  >2x 
ULN.  
ALP >2.5x ULN with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever,  and/or  rash  
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical 
Evaluation, July 2009 and other consensus guidelines, with minor modifications  
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio ; TBL = total bilirubin ; ULN = upper limit of normal.  
a All ULN values should be age adjusted (AAULN)  for parti cipants <[ADDRESS_660865] results return to baseline and if a self -limiting 
non-drug etiology is identified. Otherwise, study intervention should be discontinued.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
45 7.1.2.  Temporary Discontinuation of Study Intervention   
Temporary withholding of study intervention is requir ed if the participant meets any of the 
following infection -related criteria during the study:  
● Serious or opportunistic infections, as defined in Section 5.2. Study intervention is 
to be withheld until resolution of all acute clinical signs and symptoms, and 
completion of all appropriate anti -infective treatment.  
● HBV DNA results that are reported as positive, or as detecting HBV DNA, but 
HBV  DNA is below the level of quantification. In this situation, the sponsor’s 
designated medical monitor should be contact[CONTACT_81261]’s status. 
HBV DNA testing is to be repeated as soon as is feasible. If HBV DNA is 
confirmed as positive, the partic ipant must be permanently discontinued from 
study intervention  as described in Section 7.1. 
 If a pa rticipant <18 years of age loses a clinically significant amount of weight  
(below 40  kg), the investigator should assess rationale for weight loss and use 
clinical judg ment  to determi ne if the pa rticipant  should temporarily discontinue  
the treatment.  
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study : 
● at any time at the participant’s  own request  
● at the request of the participant’s  designee (for example, parents or legal 
guardian)  
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrolled  in any other clinical study involving an investigational product , or 
enrolled  in any other type of medical research judged not to be scientifically or 
medically compatible with this study , and  
● if the participant , for any reason, requires treatment with a therapeutic agent that 
is prohibited by [CONTACT_51992] . In this case , discontinuation from the study 
occurs prior to introduction of the new  agent . 
At the time of discontinuing from the study, the participant will complete  procedures for an early 
discontinuation visit and post-treatment follow -up, if applicable,  as shown in the S oA. If the 
participant has not already discontinued the study int ervention, the participant will be 
permanently discontinued from the study intervention at the time of the decision to discontinue 
the study.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660866] participants who fail to return for a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
47 8. Study Assessments and Procedures   
● Study procedures and their timing are summarized in the SoA.  
● Immediate  safety concerns  should be discussed with the s ponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study condu ct. 
● All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participant s screened and to confirm 
eligibility or  record reasons for sc reening failure, as applicable.  
8.1. Efficacy Assessments   
8.1.1.  Eczema Area and Severity Index   
The EASI is an investigator -reported , 20-item scale  that evaluates 2 dimensions of AD: extent of 
disease at 4 body regions (head  or neck, trunk, upper and lower extremities) and  4 clinical signs 
(erythema, induration  or papulation, excoriation, and lichenification ). The clinical signs are 
assessed for severity on a scale of 0 (absent) to 3 (severe).  
The scores are added up for each of the 4 body regions. The assigned percentages of BSA for 
each section of the body are 10% for head  or neck, 20% for upper extremities, 30% for trunk, 
and 40% for lower extremities, respectively. Each subtotal score is multiplied by [CONTACT_510923].  
In addition, an area score of 0 to  6 is assigned for each body region, depending on the percentage 
of AD -affected skin in that area: 0 (none), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 
(50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Each of the body area scores is multiplied 
by [CONTACT_510924]. The resulting EASI ranges from [ADDRESS_660867] score 
indicating worse severity of AD (Hanifin et al. 2001). The recall period of this scale is present 
time.  
Assessors must be trained and certified by [CONTACT_510925]. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
8.1.2.  Investigator’s Global Assessment (IGA)   
The IGA is an investigator -reported , single -item scale that rates the severity of the participant’s 
AD. The IGA is composed of a 5 -point scale ranging from 0 (clear) to 4 (sever e), and a score is 
selected using descriptors that best describe the overall appearance of the lesions at a given time 
point.  
Assessors must be trained and certified by [CONTACT_81265]. A 
single assessor should be assigned t o each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
48 8.1.3.  Body Surface Area (BSA)   
BSA is an investigator -reported assessment, which estimates the extent of disease or skin 
involvement of a participant ’s AD. BSA is expressed as a percentage of total body surface and 
will be reported by [CONTACT_81266]. The recall period of this assessment is present time.  
Assessors must be trained and certified by [CONTACT_81265]. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring  
8.1.4.  Face -Investi gator’s Global Assessment (F -IGA)   
The F -IGA is an investigator -administered, single -item scale that rates the severity of the 
participant’s AD on the face. The F -IGA is composed of a 5 -point scale ranging from 0 (clear) to 
4 (severe), and a score is selected using descriptors that best describe the overall appearance of 
the facial lesions at a given time point.  
Assessors must be trained and certified by [CONTACT_81265]. A 
single assessor should be assigned to each participant for as many visits as possible to avoid 
inter-assessor variability in scoring. The recall period of this assessment is present time.  
8.1.5.  Post-inflammatory Dys chromia Scale  (PDS)   
The PDS is an investigator assessment of cutaneous post -inflammatory hyperpi[INVESTIGATOR_119065]/or hypopi[INVESTIGATOR_510902] . This is a measure of post -
inflammatory cutaneous change; as such, pi[INVESTIGATOR_510903]. Areas of normal pi[INVESTIGATOR_371], with no post -inflammatory hyper - or 
hypo - pi[INVESTIGATOR_371], will receive a score of 0.  Areas of post -inflammatory hyperpi[INVESTIGATOR_371], as 
compared to adjacent normal skin tone (0), should receive a score of 1 (mild/barely perceptible 
hyperpi[INVESTIGATOR_371]), 2 (moderate/clearly perceptible hyperpi[INVESTIGATOR_371]) or 3  (severe/prominent 
hyperpi[INVESTIGATOR_136175] n). Areas of post -inflammatory hypopi[INVESTIGATOR_371], as compared to adjacent 
normal skin tone (0), should receive a score of -1 (mild/barely perceptible hypopi[INVESTIGATOR_371]), -2 
(moderate/clearly perceptible hypopi[INVESTIGATOR_371]) or -3 (severe/prominent hypopi[INVESTIGATOR_116762]). 
8.1.6.  Patient-Oriented SCORing Atopic Dermatitis ( PO-SCORAD)   
The PO -SCORAD is a patient -reported scale  used to evaluate the condition of a patient’s eczema 
over the last 3 days in both adults and adolescent  participants . Questions cover the spread of the 
eczema over the body’s surface, the severity of dry skin outside of eczema -affected areas, the 
symptom intensity on eczema -affected areas (including redness /darkness , swelling, oozing/scabs, 
scratch marks, and thickening of the skin), the intensity of eczema -related itching, and trouble 
sleepi[INVESTIGATOR_007]. There are 9 items, and response options vary across each item. For the questions about 
symptom intensity, an accompanying user guide shows visual and descriptive anchors for each 
response option. The PO -SCORAD total score ranges from 0 to 104, with higher scores 
indicating more severe AD  (Stalder et al. 2011 ; Faye  et al. 2020 ). The recall period of this scale 
is over the last 3 days. 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
49 8.1.7.  Prur itus NRS   
The Pruritus Numeric Rating Scale (NRS ) is a participant -reported , single -item, daily,  11-point 
scale . The Pruritus NRS is  used by [CONTACT_510926] 24 
hours with 0 indicating “No itch” and 10 indicating “Worst itch imaginable.” Assessment s will 
be recorded daily by [CONTACT_2299] . The minimal clinically important change is 3 points.  
(Yosipovitch et al. 2019 ; Yosipovitch  et al. 2021 ). 
Participants will record the pruritus assessments daily using an electronic diary at home. As 
indicated in the SoA (Section 1.3), initial electronic diary entries for Pruritus NRS should be 
completed a minimum of [ADDRESS_660868] night . The Sleep -Loss Scale is rated based 
on a 5 -point Likert scale (0 [not at all]  to 4 [unable to sleep at all ]). Assessment  will be recorded 
daily by [CONTACT_2299] . The minimal clinically important change is 3 points.  (Yosipovitch  et al. 
2021) . 
Participants will record the pruritus assessments daily using an electronic diary at home . As 
indicated in the SoA (Section 1.3), initial electronic diary entries for Sleep -Loss S cale should be 
completed a minimum of 4 of 7 days before baseline . 
8.1.9.  Skin Pain Numeric Rating Scale (Skin Pain NRS)   
The Skin Pain NRS is a participant -reported , 11-point horizontal scale anchored at 0 and 10, with 
0 representing “no pain” and 10 representing “worst pain imaginable.” Overall severity of a 
participant’s skin pain is indicated by [CONTACT_80210] 24 hours . Assessment will be recorded daily by [CONTACT_2299]  (Newton et 
al. 2019 ; Silverberg  et al. 202 1). 
8.1.10.  Patient -Oriented Eczema Measure (POEM)   
The POEM is a simple, participant -reported , 7-item scale that assesses disease severity in 
children and adults. Participants respond to questions about the frequen cy of 7 symptoms 
(itching, sleep disturbance, bleeding, weepi[INVESTIGATOR_007]/oozing, cracking, flaking, and dryness/roughness) 
over the past week. Response categories include “No days,” “1 -2 days,” “3 -4 days,” “5 -6 days,” 
and “Every day” with corresponding scores of 0,  1, 2, 3, and 4, respectively. Scores range from 0 
to 28, with higher total scores indicating greater disease severity (Charman et al. 2004).  
8.1.11.  Dermatology Life Quality Index/Children’s Dermatology Life Quality Index 
(DLQI/ cDLQI )  
The Dermatology Life Quality Index (DLQI ) is a simple, participant -reported , 10-item, QoL 
questionnaire in adults that covers 6 domains (symptoms and feelings, daily activities, leisure, 
work and school, personal relationships, and treatment ). The recall period of this scale is over the 
“last week.” Response categories include “not at all,”, “a little”, “a lot,” and “very much,” with 
corresponding scores of 0, 1, 2, and 3, respectively, and unanswered (or “not relevant”) 
responses scored as 0. Scores range from 0 to 30 with higher scores indicating greater 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660869] on a 
participant’s health -related QoL (Hongbo et al. 2005), and a 4 -point change from baseline is 
considered as the minimal clinically important difference threshold (Khilji et al. 2002; Basra et 
al. 2015).  
Participants <16 years at baseline will complete the children’s  DLQI ( cDLQI ) and should 
continue to complete the cDLQI for the duration of the study.  
8.1.12.  Atopic Dermatitis Control Tool (ADCT )  
The Atopic Dermatitis Control Tool (ADCT ) is a patient -reported,  simple, brief tool for adults 
and adolescents  that evaluates [ADDRESS_660870] week : 
overall severity of symptoms, days with intense epi[INVESTIGATOR_81221], intensity of bother, problem 
with sleep, impact on daily activities, and impact on mood or emotion s. Each of the [ADDRESS_660871] 
items has a score range from 0 (no problem) to 4 (worst), rating the severity of each concept; the 
total score ranges from 0 to 24, which is the summation of the responses to all the items.  A score 
of ≥7 points was derived as the thre shold to identify patients “not in control”.  The threshold for 
meaningful within -person change was estimated to be 5 points  (Simpson  et al. 2019 ; Pariser  et 
al. 2020 ). 
8.1.13.  Work Productivity and Activity Impairment Questionnaire –Atopic Dermatitis 
(WPAI -AD)  
The Work Productivity and Activity Impairment Questionnaire –Atopic Dermatitis (WPAI -AD) 
is a participant -reported , 6-item questionnaire that records impairment due to AD over the past 7 
days in adolescents and adults. The WPAI -AD consists of 6 items grouped into 4 domains: 
absenteeism (work time missed), presenteeism (impairment at work/reduced on the job 
effectiveness), work productivity loss (overall work impairment/absenteei sm plus presenteeism), 
and activity impairment. Absenteeism, presentism, and work productivity will only be reported 
by [CONTACT_510927] (working for pay) at the time of the scale completion.  The 
recall period for the scale is over the past  7 days . Scores are calculated as impairment 
percentages (Reilly et al. 1993), with higher scores indicating greater impairment and less 
productivity.  
8.1.14.  Participant -Reported  Satisfaction  Question   
The question on p articipant  satisfaction asks “ How satisfied are you with this treatment’s ability 
to treat your skin condition?” The response options range from 1 (not satisfied) to 5 (completely 
satisfied).  
8.1.15.  Fitzpatrick Skin Photot ype Assessment   
The Fitzpatrick Scale is a clinician -rated scale and is based on a participant ’s cutaneous reaction 
to sun exposure and baseline skin pi[INVESTIGATOR_371] . Fitzpatrick skin ph ototypes range from I to VI, 
with a score of I indicating “always burns, does not tan , white skin tone ”, and a score of VI 
indicating “never burns, tans very easily , skin color black ” (High et al . 2012 ). Investigators will 
follow the descriptive terms included in this protocol when recording the Fitzpatrick skin 
phototype . The sun sensitivity measure  will represent  the Fitzpatrick Scale score for each 
participant. The recall period for this scale is the present time.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
51 8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
The routine safety assessments include physical examinations, clinical safety laboratory tests 
(including hematology and ch emistry), and collection of vital signs and spontaneously reported 
AEs. The study design includes a Post-treatment  Follow -Up Period with at least 1 study visit for 
safety assessments.  
8.2.1.  Clinical Safety Laboratory Tests   
● See Appendix [ADDRESS_660872] of clinical laboratory tests to be performed and the 
SoA for the timing and frequency.  
● Local anesthetics  
○ Use of local anesthetics  (e.g., EMLA cream) consistent with local prescribing 
information are permitted during the study visit to ease discomfort associated with 
venipunctures.  
● The investigator must review the laboratory results , document this review, and 
report  any clinically relevant changes occurring during the stud y as an AE . The 
laboratory results must be retained with source documents unless a Source 
Documen t Agreement or comparable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory f indings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_41411]'s condition.  
● All laboratory tests with values considered clinically significantly abnormal 
durin g participation in the study or within [ADDRESS_660873] dose of study 
intervention should be repeated until the values return to normal or baseline or are 
no longer considered clinically significant by [CONTACT_10982].  
○ If such values do not return to normal  or baseline within a period of time 
judged reasonable by [CONTACT_093], the etiology should be identified and 
the sponsor notified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2, must 
be conducte d in accordance with the SoA , standard collection requirements , 
and laboratory manual . 
● If laboratory values from non -protocol specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant manage ment or are considered clinically significant by [CONTACT_1275] , for example , SAE or AE or dose modification, then  report the 
information as an AE . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
52 8.2.2.  Hepatic Safety   
Close hepatic monitoringa 
Laboratory tests (Appendix 6), including alanine aminotransferase  (ALT), aspartate 
aminotransferase  (AST ), alkaline phosphatase  (ALP ), total bilirubin  (TBL ), direct bilirubin , 
gamma -glutamyl transferase , and creatine kinase , should be repeated within 48 to 72 hours to 
confirm the abnormality and to determine if it is increasing or decreasing, if 1 or more of these 
conditions occur:  
If a participant with baseline 
results of...  develops the fol lowing elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase ; ALT = alanine aminotransferase; AST = aspartate aminotransferase ; 
TBL = total bilirubin ; ULN = upper limit of normal . 
a All ULN values should be age adjusted (AAULN)  for participants <18 years of age.  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_510928] -designated medical monitor. At a minimum, this evaluation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension,  or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, and history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should  be done at a frequency of 
1 to 3 times weekly, based on the participant ’s clinical condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant ’s clinical condition and la b results stabilize.  Monitoring of ALT, AST, ALP, and TBL 
should continue until levels normalize or return to approximate baseline levels.  For participants 
<18 years of age, s pecial care should be taken to minimize the volume of blood taken during 
hepatic monitoring.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
53 Comprehensive hepatic evaluationa 
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevat ions:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs  or symptomsb, or 
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs  or symptomsb, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALP = alkaline phosphatase ; ALT = alanine aminotransferase; AST = aspartate aminotransferase ; 
TBL = total bilirubin ; ULN = upper limit of normal . 
a All ULN values should be age adjusted (AAULN) for participants <18 years of age.  
b Hepatic signs  or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdomi nal pain, fever, and/or 
rash. 
For Adult Participants  (≥18 years old)  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalized ratio ; 
tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging 
study , for example, ultrasound or computed tomography scan.  
Based on the patient ’s history and initial results, further testing should be considered in 
consu ltation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson ’s disease, blood alcohol levels, urinary eth yl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator ’s assessment of the 
participant ’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist consult ation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
For Adolescent Participants  (<18 years old)  
At a minimum, this evaluation should include physical examination and  a thorough medical 
history, as outlined above, as well as tests for prothrombin time -international normalized ratio  
and direct bilirubin, if total bilirubin was elevated.  
Based on the participant ’s age, medical history and initial results, further testing  should be 
considered in consultation with the Lilly -designated medical monitor, including tests for viral 
hepatitis A, B, C, E; autoimmune hepatitis; or an abdominal imaging study , for example, 
ultrasound, MRI, or computed tomography  scan). Consider addit ional tests, based on the medical 
history and clinical pi[INVESTIGATOR_1103], including tests for hepatitis D virus , cytomegalovirus , Epstein -Barr 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
54 virus , acetaminophen levels, acetaminophen protein adducts, urine toxicology screen, Wilson ’s 
disease, blood alcohol levels , urinary ethyl glucuronide, and blood phosphatidylethanol. Special 
care should be taken to prioritize more pertinent blood tests and minimize the volume of blood 
taken during hepatic evaluation. Based on the circumstances and the investigator ’s assessment  of 
the participant ’s clinical condition, the investigator should consider referring the participant for a 
pediatric hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatography , endoscopic retrograde cholangiopancreatograph y, cardiac 
echocardiogram, or a liver biopsy as deemed appropriate for the clinical condition and 
participant ’s age.  
Additional hepatic data collection (hepatic safety CRF) in study participants 
who have abnormal liver tests during the study  
Additional hep atic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:a 
 Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests , (if baseline 
ALT <1.5x ULN)  
o In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests  
 Elevated TBL to ≥2x ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert ’s syndrome)  
o In participants with baseline TBL ≥1.5x ULN, th e threshold should be TBL ≥2x 
baseline  
 Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
o In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood tests  
 Hepatic event considered to be a SAE  
 Discontinuation of study drug due to a hepatic event  
NOTE : the interval between the [ADDRESS_660874] values should be age adjusted (AAULN) for participants <18 years of age.  
8.2.3.  Hepatitis B Testing and Monitoring   
As specified in the SoA (Section 1.3), initial testing for HBV infection includes HBsAg and 
hepatitis B core antibody  (HBcAb .). 
● If HBsAg is positive, the participant is excluded.  
● If HBsAg is negative and HBcAb  is negative, t he participant is not excluded.  
● If HBsAg is negative and HBcAb  is positive, further testing for HBV DNA is 
required.  
○ If the screening HBV DNA is positive, the participant is excluded.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
55 ○ If the screening HBV DNA is negative, the participant is not exclu ded. Repeat 
testing for HBV DNA is required at least every 3 months during the study as 
described in the S oA. 
Management of enrolled participants with detectable HBV DNA during the study  
If HBV DNA is detected, study intervention will be temporarily withheld or permanently 
discontinued, as described in Sections  7.1.2  and 7.1, and the participant should be referred  for 
appropriate  follow -up medical care . 
8.2.4.  Hepatitis C Testing   
As specified in the SoA (Section 1.3), initial testing for HCV infection includes testing for 
antibodies to HCV (anti-HCV ). 
● If anti -HCV is positive, a test for circulating HCV RNA is required.  
● If HCV RNA test is negative, the participant is not excluded.  
● If HCV RNA test is positive, the participant is excluded (see Section 5.2). 
Participants who have had HCV infection and have been successfully treated , defined as a 
sustained virologic response (HCV RNA by [CONTACT_81273] 24 
weeks following treatment completion) are not excluded on the basis of HCV as long as HCV 
RNA test is negative at screening.  
If HCV RNA is detected d uring the study, the study intervention will be discontinued 
(Sectio n 7.1), and the participant should receive  appropriate  follow -up medical care.  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints   
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs  and  
 PCs 
These eve nts will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant's  legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the se definition s and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention  or study (see Section 6). 
Care will be taken not to introduce bias when detecting events . Open -ended and n on-leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs and AEs of special interest (as defined in Section 8.3.3 ) will 
be followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow -up (as defined in Section 7.3). For PCs, the investigator is responsible for ensuring 
that follow -up includes any sup plemental investigations as indicated to elucidate the nature 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
56 and/or causality.  Further information on follow -up procedures is provided in Section 10.3, 
Appendix  3. 
8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collec tion 
Stop  Timing  for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -up 
Method of 
Reporting  
Adverse Event  
AE Signing  of 
the ICF  Participation  
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing  of 
the ICF  Start of 
intervention  Within 24 hours  of 
awareness  SAE paper form  SAE paper 
form  
SAE  and SAE 
updates  – after 
start of study 
intervention  Start of 
intervention  Participation  
in study has 
ended  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660875] dose 
of study 
intervention.  Within 24 hours (see 
Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
Product Complaints  
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed and dated by 
[CONTACT_093]  N/A 
PC, (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event; ICF = informed consent form ; N/A = not applicable ; PC = product complaint 
SAE = serious adverse event . 
a Serious adverse events  should not be reported unless the investigator deems them to be possibly related to study 
treatment  or study participation . 
8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this stud y. This applies only to male participants who receive study 
intervention . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
58 ● After learning of a pregnancy in the female partner of a study participant, the 
investig ator  
o will request  a consent  or assent  to release information  from the pregnant 
female partner directly, and 
o within [ADDRESS_660876] pregnancy 
information on the appropriate form and submit it to the sponsor . 
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the follow -up will be no longer than 6 to 8  weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of  gestational age,  fetal status (presence or absence of 
anomalies ), or indication for the procedure.  
Female participants who become pregnant  
● The in vestigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial i nformation 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours  of learning of a participant ’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, fo llow-up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported , regardless of gestational age,  fetal 
status (presence or absence of anomalies) or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <2 0 weeks gestational age) or still b irth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
● Any post-study pregnancy related SAE considered reasonably related to the study 
intervention by [CONTACT_510929] r as described in 
protocol Section  8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
● Any female participant w ho becomes pregnant while participating in the study 
will discontinue study intervention . If the participant is discontinued from the 
study, follow the standard discontinuation process and continue directly to the 
follow -up phase. The follow -up on the preg nancy outcome should continue 
independent of intervention or study discontinuation.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660877] occur:  
● The sponsor and the relevant institutional review board /independent ethics comm ittee 
(IRB/IEC ) give written approval . 
● The participant gives signed informed consent  (and assent, as applicable) . 
● The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and the participant’s  offspring . 
8.3.3.  Adverse  Events of Special Interest   
The following TEAEs will be designated AE of special interest ( AESI ): 
 conjunctivitis  
 herpes infection or zoster, and  
 parasitic infection or an infection related to an intracellular pathogen.  
If these AESIs are reported, sites will be prompted to collect additional data . Participant records 
must include any follow -up information regarding these AESI. Study  intervention  should be 
discontinued if an  AE is deemed persistent and if continuation of  study intervention would not be 
in the best interest of the participant . Discuss discontinuation of study intervention  with the 
sponsor or designee prior to implementation.  
[IP_ADDRESS].  Infections, Including  Serious Infec tions and Opportunistic Infections   
Completion of the Infection CRF page is required for each infection reported as an AE or SAE. 
The sponsor will identify infections considered to be opportunistic based on the article by 
[CONTACT_81274]. (2015) ( Section 10.9, Appendix 9). 
8.3.4.  Facial Dermatitis   
Completion of the facial dermatitis follow -up CRF page i s required for each facial dermatitis 
event reported as an AE or SAE.  
8.3.5.  Hypersensitivity   
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersens itivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood samples should be  
collected as described in Section  10.2.1 . Laboratory results are provided to the sponsor via the 
central laboratory.  
8.3.6.  Injection Site Reactions   
Symptoms and signs of a local injection site reaction may include erythema, induration, pain, 
pruritus, and edema . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
60 If an injection site reaction  is reported by a participant or site staff, the injection site reaction  
CRF will be used to capture  additional information about this reaction (for example, injection -
site pain, degree and area of erythema, induration, pruritis , and edema).  
8.4. Pharmacokinetics   
At the visits and times specified in the SoA, venous blood samples will be collected and stored 
for potential analysis of serum co ncentrations of lebrikizumab . 
Samples will be stored at a facility designated by [CONTACT_510930] a later da te 
at a laboratory approved by [CONTACT_4682] a validated enzyme -linked immunosorbent assay 
method.  
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456]. 
The actual data and time (24 -hour clock time) of each samp le and the most recent lebrikizumab 
dose prior to PK blood draw must be recorded.  
Sample retention is described in Section 10.1.[ADDRESS_660878] 
participant visit for the study. During this time, samples remaining after the bioanalysis may be 
used for exploratory analyses such as  bioanalytical assay validation or cross -validation exercises.  
8.5. Pharmacodynamics   
Pharmacodynamic parameters a re not evaluated in this study . 
8.6. Genetics   
A blood  sample for DNA isolation will be collected from participants.  
See Section 10.5, Appendix 5  for Information regarding genetic research  and Section  10.1.11  for 
details about  sample retention and c ustody . 
8.7. Biomarkers   
 Serum samples will be collected to discern responder variability within the study and to 
track response variability to lebrikizumab . Biomarkers will include but not limited to 
 
Samples will be collected acc ording to the schedule described 
in the SoA and as detailed in laboratory manual provided separately to sites . 
 The s ponsor  may store samples according to Section 10.1.11 . Additionally, with 
participants’ consent, samples may be used for further research by [CONTACT_510931], the development of related or new treatments, or research methods.  
8.8. Immunogenicity Assessments   
At the visits and times specified in the SoA, venous blood samples will be collected for the 
purpose of determining  antibody production against lebrikizumab. To aid interpret ation of  these  
results, a blood sample for PK analysis will be collected at the same time points . 
Approved on 29 Sep 2023 GMT
CCI
CONFIDENTIAL  J2T-MC-KGBP (c) 
61 All samples for immunogenicity should be taken pre-dose when applicable and possible. 
Instructions for the collection and handling of blood samples will be provided by [CONTACT_456] . 
The actual date and time (24 -hour clock time) of each sample collection will be recorded.  
Immunogenicity samples will be stor ed at a facility designated by [CONTACT_510932] a later date using  a validated assay designed to detect anti-drug antibod ies (ADAs ) in 
the presence of lebrikizumab at a laboratory designated by [CONTACT_456].  Samples may also be 
used for th e development and control of an immunogenicity assay.  
Treatment -emergent ADA s are defined in Section [IP_ADDRESS] . 
Sample retention is described in  Section 10.1.11 . 
8.9. Health Economic s  
Health economics and/or medical resource utilization will not be collect ed as part of  this study.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660879] 75% improvement in 
baseline EASI at Week [ADDRESS_660880] atistical 
analysis will be perform ed. 
9.2. Analyses  Sets  
Participant Analysis Set  Description  
ITT population  All enrolled  participants. Participants will be included in the analyses 
according to the planned intervention.  
Safety population  All enrolled  participants who are exposed to study intervention.  
Abbreviation: ITT = intent -to-treat.  
9.3. Statistical Analyses   
9.3.1.  General Considerations   
Statistical analysis of this study will be the responsibility of Eli Lilly and Company (Lilly) or its 
designee. A detailed SAP describing the statistical methodologies will be developed by [CONTACT_510933].  
Any change to the data analysis methods desc ribed in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report ( CSR ). Additional exploratory analyses of the data will be conducted 
as deemed appropriate.  
All analyses will be descriptive. Frequencies, percentages and 90% confidence interval (CI) for 
percentages will be reported for discrete efficacy endp oints. Mean, standard deviation, minimum, 
Q1, median, Q3, maximum, and the number of participants will be reported for continuous 
efficacy endpoints. AEs, discontinuation, and other categorical safety data will be summarized 
using frequencies and percentag e. Continuous vital signs, body weight, and other continuous 
safety variables including laboratory variables will be summarized descriptively as well.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
63 9.3.2.  Primary Endpoint (s)/Estimand(s)  Analysis   
The primary endpoint is EASI  [ADDRESS_660881] is : What is the intervention effect  in percentage of participants achieving EASI  [ADDRESS_660882] an intercurrent event such as initiating rescue medication or permanently discontinuing 
treatment.  All observed data will be included in summary statistics.  All summary statistics wi ll 
be based on observed data.  
9.3.3.  Secondary Endpoint (s)/Estimand(s)  Analysis   
Secondary endpoints  specified  in Section 3 will be  analyzed similarly to the primary endpoint of 
the primary estimand , that is,  using all observed data.   
9.3.4.  Exploratory Endpoint (s) Analysis   
Other  exploratory endpoints specified in Section [ADDRESS_660883] current version of MedDRA (Medical Dictionary for Regulatory 
Activities) by [CONTACT_9313]  (or body system)  and by [CONTACT_510934]. SAEs and AEs 
that lead to discontinuation of study intervention will also be summarized.  
All clinical laboratory results wil l be descriptively summarized. Individual results that are 
outside of normal reference ranges will be flagged in data listings. Quantitative clinical 
hematology , chemistry , and urinalysis  variables obtained at the baseline to postbaseline visits 
will be su mmarized as changes from baseline. Categorical variables, including the incidence of 
abnormal values and incidence of AEs of special interest, will be summarized by [CONTACT_81279]. Shift tables might be  presented for 
selected measures.  
Observed values and changes from baseline (predose or screening if missing) for vital signs and 
physical characteristics will be descriptively summarized by [CONTACT_7206] . 
The SAP may include a dditional safety analy ses if nee ded. 
9.3.6.  Other Analyses   
[IP_ADDRESS].  Subgroup Analyses   
Subgroup  (subpopulation)  analyses of the primary and some  secondary endpoints at Week s 16 
and 24  may be conducted for  intent -to-treat set. Subgroup to be evaluated may include baseline 
severity, sex, age, race, Fitzpatric k skin type.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
64 Definitions for the levels of the subgroup variables and any additional  subgrou p analyses will be 
defined in the SAP. All subgroup analyses will be descriptive and should be treated as 
exploratory . 
[IP_ADDRESS].  Biomarker Analyses   
Biomarker analyses will be described in  the SAP.  
[IP_ADDRESS].  Pharmacokin etic Analyses   
Pharmacokinetic  samples will be stored and may be later assessed. If assessed,  pharmacokinetic 
analyses may be described in the SAP  
[IP_ADDRESS].  Immunogenicit y Assessments   
Immunogenicity samples will be stored and may be later assessed. If assessed, the frequency and 
percentage of participants with pre-existing anti-drug antibody ( ADA ) and who are treatment -
emergent ADA positive (TE ADA+) to lebrikizumab  will be tabulated.  
Treatment -emergent ADAs are defined as participants  
 with a 2-fold (1 dilution) increase in titer than the minimum required dilution if no 
ADAs were dete cted at baseline (treatment -induced ADA), or  
 with a 4 -fold (2 dilutions) increase in titer compared with baseline if ADAs were 
detected at baseline (treatment -boosted ADA).  
The distribution of titers and frequency of neutralizing antibodies (if assessed) f or TE ADA+ 
participant s may also be tabulated.  
The relationship between the presence of ADA  and PK parameters, efficacy response or safety to 
lebrikizumab  may also be assessed.  
Additional details may be provided in the SAP.  
9.4. Interim Analys is  
One interim analysis  (primary lock) will be conducted after all enrolled participants  have been 
evaluated at Week 16 or discontinu ed prior to Week 16. This interim database lock  will include 
all efficacy and safety data collected by [CONTACT_510935] e. Due to the open -label and descriptive 
nature of this study, this is no unblind nor alpha adjustment . 
Additional analyses and snapshots of study data may be performed to fulfill the ne ed for 
regulatory interactions or publication purposes.  
The SAP will describe the planned int erim analyses in greater detail.  
9.5. Sample Size Determination   
Based on the available data, EASI 75 response rate is approxim ately 50%. A total sample size of 
at least 80 enrolled participants will provide >95% probability that the half-width of the 2-sided 
90% CI of EASI [ADDRESS_660884] 10%.  This study will enroll approximately 95 participan ts to 
enable  exploratory biomarker analyses.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
65 The 2-sided 90% CI  of EASI 75 response rate s based on Wilson score method  are summarized 
for a sample size of 80 participants in the  table  below . The C Is are provided as reference rathe r 
than a basis of any decision criteria . 
Estimated 90% Confidence Interval  with  Sample Size of 80 Participants  
Response Rate  (%) Lower Limit  (%) Upper Limit  (%) 
40 31.46 49.19 
45 36.16 54.16 
50 40.96 59.04 
55 45.84 63.84 
60 50.81 68.54 
65 55.87 73.15 
70 61.03 77.66 
 
 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
66 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
● This study will be conducted in accordance with t he protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences International Ethical Guidelines  
○ Applicable ICH  GCP Guidelines  
○ International Organization for Standardization [ZIP_CODE]  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IR B/IEC by [CONTACT_10998]/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants . 
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ Notifyi ng the IRB/IEC of SAEs  or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations , ICH 
guideline s, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations  
● Investigator sites are compensated for participation in the study  as detailed in the 
clinical trial agreement . 
10.1.2.  Financial Disclos ure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate  financial 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
67 certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informe d Consent Process   
● The investigator or the investigator’s  representative will explain the nature of the 
study , including the risks and benefits,  to the participant (or the participant’s 
legally authorized representative ) and answer all  questions regarding the study.  
● Participants must be informed that their participation is voluntary. Participants (or 
the participant’s legally authorized representative ) will be require d to sign a 
statement of informed consent /assent  that meets the requirements of 21 Code of 
Federal Regulations  50, local regulations, ICH guidelines, privacy and data 
protection requirements, where applicable, and the I RB/IEC or study center . 
● For adult p articipants, t he medical record must include a statement that written 
informed consent was obtained before the participant was enter ed in the study and 
the date the written consent was obtained. The authorized person obtaining the 
informed consent must als o sign the ICF.  
● For adolescent participants, t he medical record must include a statement that legally 
acceptable representative or parent(s) consent and child/adolescent assent (if deemed 
appropriate by [CONTACT_81281]) was obtained before the partic ipant was enrolled in 
the study and the date the written consent was obtained. The medical record should also 
describe how the clinical investigator determined that the person signing the ICF was the 
participant’s legally acceptable representative or paren t(s). The acceptable person 
obtaining the informed consent must also sign the ICF.  Adolescent  participants who 
become 18  years of age  while on study, will need to re-consent.  
● Participants (or their legally acceptable representative, parent(s), or legal 
guardian ) must be reconsented (or re-assented) to the most current version of the 
ICF(s) during th eir participation in the study.  
● A copy of the ICF(s) must be provided to the participant (or the participant’s 
legally authorized representative ) and is kept on file . 
Participants who are rescreened are required to sign a new ICF.  
10.1.4.  Data Protection   
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records , datasets , or tissue samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identi fiable will not be transferred.  
● The participant must be informed that the participant’s  personal study -related data 
will be used by [CONTACT_10999]. The 
level of disclosure must also b e explained to the participant  who will be required 
to give consent for their data to be used as described in the informed consent . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
68 ● The participant must be informed that their medical records may be examined by 
[CONTACT_103083], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
● The sponsor has processes in place to ensure da ta protection, information security , 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
10.1.5.  Dissemination of Clinical Study Data   
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].  
Data  
The sponsor provides access to  all individual participant data collected during the trial, after 
anonymization, with the exception of pharmacokinetic or genetic data.  Data are available to 
request [ADDRESS_660885], see the instructions provided at www.vivli.org.  
10.1.6.  Data Quality Assurance   
● All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electronically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The inv estigator must maintain accurate documentation (source data) that 
supports the information entered in  the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to s ource data 
documents.  
● Quality tolerance limits (QTLs) will be pre-defined to identify systematic issues 
that can impact participant safety and/or reliability of study results. These pre-
defined parameters will be monitored during the study and important excursions  
from the QTLs and remedial actions taken will be summarized in the CSR . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
69 ● Monitoring details describing strategy ( for example , risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and 
analytical risk -based monitori ng), methods, responsibilities and requirements, 
including handling of noncompliance issues and monitoring techniques are 
provided in the Monitoring Plan . 
● The sponsor or designee is responsible for the data management of this study 
includin g quality checking of the data.  
● The sponsor assumes accountability for actions delegated to other individuals ( for 
example , contract research organizations ). 
● Study monitors will perform ongoing source data verification to confirm that data 
transcribed  into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regu latory requirements.  
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_510936] a 
longer retention period. No records may be destroyed during the retention period 
without the written approval of the sponsor. No records may be transferred to 
another loca tion or party without written notification to the sponsor . 
● In addition, sponsor  or its representatives will periodically check a sample of the 
participant  data recorded against source documents at the study site. The study 
may be audited by [CONTACT_81284], and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by [CONTACT_82413] -provided EDC  system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003] . 
Additionally, the skin assessment using the Fitzpatrick Skin Type scale will be collected by [CONTACT_350524] , via a paper source document and will be transcribed by [CONTACT_81287] . 
Additionally, electronic clinical outcome assessment  (eCOA) data ( participant -focused outc ome 
instrument ) will be directly recorded by [CONTACT_2299] /investigator site personnel , into an 
instrument ( for example, hand -held smart phone or tablet ). The eCOA data will serve as the 
source documentation , and the investigator does not maintain a sepa rate written or electronic 
record of these data.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
70 Data collected via the sponsor -provided data capture system (s) will be  stored at third -parties. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data  capture system (s). Prior to decommissioning, the investigator will receive or access 
an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s da tabase system and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.7.  Source Documents   
● Source documents provide evidence for the existence of the participant  and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported  on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
● Definition of what constitutes source data can be found in Sectio n 10.1.[ADDRESS_660886] site open  and will be the study start date.  
Study or Site Termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and  study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
For study termination:  
● Discontinuation of further study intervention development  
For site termination:  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
71 ● Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
● Inadequate recruitment (evaluated after a reasonable amount of time)  of 
participants by [CONTACT_093]  
● Total number of partic ipants included earlier than expected . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the r eason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.9.  Publication Policy   
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.10.  Investigator Information   
Researchers with appropriate education, training, and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical trial . 
10.1.11.  Sample Retention   
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of lebrikizumab or after  lebrikizumab become(s) commercially available moderate -to-severe AD. 
 
Sample Type  Custodian  Retention Period after 
Last P articipant  Visit  
Biomarkers  Sponsor or Designee  7 years  
PK Sponsor or Designee  1 year 
Genetics  Sponsor or Designee  7 years  
Immun ogenic ity Sponsor or Designee  7 years  
 Abbreviation: PK = pharmaco kinetics . 
 
   
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
72 10.2. Appendix 2: Clinical Laboratory Tests   
● The tests detailed in the table below will be performed by [CONTACT_2237] . 
● In circumstances where the sponsor approves local laboratory testing in lieu of 
central laboratory testing (in the table below), the local laboratory must be 
qualified in accordanc e with applicable local regulations.  
● Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
● Investiga tors must document their review of the laboratory safety results . 
Clinical Laboratory Tests   Comments  
Hematology  Assayed by [CONTACT_11007] -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count ( RBCs )   
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Absolute Neutrophil Count (Calculation)  
(Definition - include Segs and Bands or 
Segs, Bands and other immature cells)    
Leukocytes (WBCs)    
Differential    
Percent and absolutes count of:   
 Neutrophils, segmented    
 Neutrophils, bands   
 Lymphocytes    
 Monocytes    
 Eosinophils    
 Basophils    
Platelets    
Cell morphology (RBCs and WBCs)    
    
Clinical Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Total bilirubin    
Direct bilirubin    
ALP    
ALT    
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660887]    
GGT    
BUN    
Creatinine    
CK   
Uric acid    
Total protein    
Albumin    
Calcium    
Phosphorus    
LDH    
    
Hormones (female)    
Serum Pregnancy  Assayed by [CONTACT_11007] -designated laboratory.  
Urine Pregnancy  Assayed and Evaluated locally  
    
HIV and Hepatitis Serology  Assayed by [CONTACT_11007] -designated laboratory  
HIV testing    
HCV testing:    
 HCV antibody    
 HCV RNA    
HBV testing:    
 HBV DNA  Performed only for participants who test positive for 
HBcAb .  
 HBcAb    
 HBsAg    
 HBsAb    
Exploratory Biomarker s  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative sites.  
   
Immunoglobulins  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative sites.  
IgE (Serum)    
    
Genetics Sample  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative sites.  
    
Exploratory Biomarker storage samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative sites.  
Serum    
  
Approved on 29 Sep 2023 GMT
CCI
CONFIDENTIAL  J2T-MC-KGBP (c) 
74 Clinical Laboratory Tests   Comments  
Immunogenicity  (ADA) samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigative sites.  
Anti-LY3650150 antibodies   
Pharmacokinetic Samples  – LY3650150 
concentration  Assayed by [CONTACT_11007] -designated laboratory.  
Results w ill not be provided to the investigative sites.  
 
Abbreviations: ADA = anti -drug antibodies; ALP = alkaline phosphatase ; ALT = alanine aminotransferase ; AST = 
aspartate aminotransferase ; BUN = b lood urea nitrogen ; CK = c reatine kinase ; GGT = Gamma -glutamyl  
transferase ; HBcAb  = hepatitis B core antibody ; HBsAb = hepatitis  B surface antibody ; HBsAg = hepatitis  B 
surface antigen ; HBV = hepatitis  B virus; HCV = hepatitis  C virus; HIV = human immunodeficiency virus; IgE = 
immunoglobulin E; IL = interleukin ; LDH = lactic dehydrogenase ; PK = pharmacokinetics; RBC = red blood 
cells; WBC = white blood cells.  
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event   
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hyperse nsitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain follow -up predose samples at the next regularly scheduled laboratory sample collection 
(ideally prior to the next dose after the event) to assess post -event return -to-baseline values.  
 
Timing  Labo ratory Test a 
Collect from 30 minutes to 4 hours 
after the start of the event.  
● NOTE : The optimal 
collection time is from [ADDRESS_660888] only if not already collected 
on the same day as the event.  
● NOTE : If collecting, 
collect up to 12 hours after the 
start of the event.  Lebrikizumab  anti-drug antibodies (ADA)  
Lebrikizumab concentration  
a All samples for hypersensitivity testing will be assayed by [CONTACT_11007] -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protoco l deviation.  
What information to record  
Record the date and time when the samples are collected.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
75 Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management.  
 
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
76 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
 The definitions and procedures detailed in this appendix are in accordance with 
International Organization for Standardization  [ZIP_CODE].  
 Both the investigator and the sponsor will comply with all local medical device 
reporting  requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_660889] of 
sponsor medical devices).  
10.3.1.  Definition of AE   
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship 
with the study intervention. An AE can therefore be any unfavo rable  and 
unintended sign (including an abnormal laboratory finding), symptom, or disease  
(new or exacerbated)  temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) 
product . 
 An AE is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory finding) in study 
participants, users, or other persons, whether or not related to the investigational 
medical device. This definition includes events related to the investigational 
medical device or compa rator and events related to the procedures involved except 
for events in users or other persons, which only include events related to 
investigational devices.  
 
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology  or clinical chemistry) or other 
safety assessments ( for ex ample , electrocardiogram , radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not 
related to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed afte r study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of eit her study 
intervention or a concomitant medication. Overdose per se will not be reported as 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
77 an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdose s should be reported regardless of sequelae.  
 Lack of e fficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be r eported as AE or SAE if they fulfil l the definition o f an AE 
or SAE.   
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for th e 
participant’s condition.  
 Medical or surgical procedure ( for example , endoscopy, appendectomy): the 
condition that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a  hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
 In general, hospi[INVESTIGATOR_510904] (usually involving at least an overnight stay) for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
hospi[INVESTIGATOR_61497], the AE should be considered serious.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
78  Hospi[INVESTIGATOR_5187] a pre-existing  condition that did not 
worsen from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accide ntal trauma ( for example , sprained ankle) which may interfere 
with or prevent everyday life functions but do not constitute a substantial 
disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, feta l death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised by [CONTACT_170280] -threatening or result in death or 
hospi[INVESTIGATOR_510905] i ntervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for aller gic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.   
g. Resulted in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.  
 
10.3.3.  Definition of Product Complaints   
Product Complaint  
 A PC is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness or performance of a 
study  intervention . When the ability to use the study intervention safely is impacted, 
the following are also PCs: 
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
79  Product com plaints related to study inte rventions used in clinical trials are collected to 
ensure the safety of participants, monitor quality, and to facilitate process and product 
improvements.  
 Investigators will instruct p articipants to contact [CONTACT_11010] a PC or problem with the study inte rvention  so that the situation can be assessed.  
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint  Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /PC information in the 
participant’s medical records, in accordance with the invest igator’s normal clinical 
practice . AE/SAE information is reported o n the appropriate  CRF  page and PC 
information is reported on the PC Form . 
o NOTE : An event may meet the definition of both a PC and an AE/SAE. In such 
cases, it should be reported as both a PC and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the PC Form for PCs. 
 There may be instances when copi[INVESTIGATOR_51958] . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_510906] . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:  
 Mild:  A type of adverse event that is usually transient and may require only 
minimal treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living . 
 Moderate:  A type of adverse event that is usually alleviate d with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the 
research participant . 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
80  Severe: A type of adverse event that interru pts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic 
intervention . An AE that is assessed as severe should not be confused with a SAE. 
Severe is a category utilized for rating the intensity of  an event; and both AEs and 
SAEs can be assessed as severe.  
An event is defined as “serious ” when it meets at least one of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.   
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.  The investigator will use clinical judgment 
to determine the relationship / 
 A “reasonable possibility ” of a relationship conveys that there a re facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of t he event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and h as provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor or designee . 
However, it is very important that the investigator always ma ke an assessment of 
causality for every event before the initial transmission of the SAE data to Sponsor 
or designee . 
 The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send a SAE follow -up report with the updated causality 
assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_510937]/or causality of the AE or SAE as fully as 
possible . This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
81  If a participant dies during participation in the study or during a recognized follow -
up period,  the inv estigator will provide Sponsor or designee  with a copy of any 
post-mortem findi ngs including histopathology.  
10.3.5.  Reporting of SAEs   
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form  is the preferred method to transmit 
this information to the medical monitor or the SAE coordinator . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in SAE form.  
10.3.6.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
 Prompt notification by [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will evaluate the reported SAEs, 
including confirmation of  relatedness and assessment of expectedness. The 
sponsor has processes for safety reports for identification, recording, and 
expedited reporting of suspected unexpected serious adverse reactions  
according to local regulatory requirements . The sponsor will comply with 
country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Boards (IRB)/Independent Ethics 
Committees (IEC) , and investigators.  
● An investigator who receives an investigator safety r eport describing a SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the sponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.   
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
82 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
Women of child -bearing  potential  (WOCBP ) 
Females are considered WOCBP if they have  had at least 1 cycle of menses.  
Any amount of spotting or bleeding should be considered menarche.  
Women not of child -bearing  potential  (WNOCBP)  
 females  are considered WNOCBP  if they have a congenital anomaly such as 
Mullerian agenesis,  
 are infertile due to surgical sterilization, or  
 are post menopausal . 
Examples of surgical sterilization include total hysterectomy, bilateral salpi[INVESTIGATOR_8936] -oophorectomy , 
bilateral  salpi[INVESTIGATOR_61502], or  bilateral oophorectomy . 
Postmenopausal  
The postmenopausal  state is defined  as ≥[ADDRESS_660890]. 
10.4.2.  Contraception Guidance   
Guidance for WOCBP  
This outlines the rules for WOCBP to ensure they do not become pregnant during the study.  
 
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship as their preferred and usual lifestyle:  
Must…  Must not…  
agree to either 
remai n abstinent or 
stay in a same -sex 
relationship without 
sexual relationships 
with males   use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation  
 declare abstinence just for the duration of a trial, or  
 use the withdrawal method  
 
WOCBP who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same -sex relationship as their preferred and usual lifestyle, must do the following:  
Topic  Condition  
Pregnancy testing  Have a negative serum test result at screening (or upon  a participant 
that reaches menarche  during the trial and is sexually active ) followed 
by a negative urine result within 24 hours prior to treatment exposure. 
See the protocol SoA for subsequent pregnancy testing requirements.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
[ADDRESS_660891] be used for the duration of the 
study.  
 
Examples of differ ent forms of contraception:  
Methods  Examples  
Highly effective contraception (less than 1% 
failure rate)   female sterilization  
 combination oral contraceptive pi[INVESTIGATOR_4382]  
 progestin -only contraceptive pi[INVESTIGATOR_4382] 
(mini -pi[INVESTIGATOR_4382]) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women 
<198  pounds or 90  kg) 
 total abstinence  
 vasectomy , if only sexual partner  
 fallopi[INVESTIGATOR_31077] , if confirmed 
by [CONTACT_31084][INVESTIGATOR_8913]  
 combined contraceptive vaginal ring, 
or 
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical 
sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide  
 
NOTE : The barrier met hod must include use of a 
spermicide ( that is , condom with spermicide, 
diaphragm with spermicide, and female condom 
with spermicide) to be considered effective.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
84 Methods  Examples  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, 
symptothermal)  
 withdrawal  
 post coital douche , and  
 lactational amenorrhea  
Guidance for all men 
Males may participate in this trial.  
No male contraception is required except in compliance with specific local government study 
requirements.  
 
 
 
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
85 10.5. Appendix  5: Genetics   
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolism, and excretion; mecha nism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a sample will be collected 
for DNA analysis from consenting participants.  
● DNA samples will be used for research related to lebrikizumab  or moderate -to-
severe AD and related diseases. They may also be used to develop tests/assays 
including diagnostic tests related t o lebrikizumab  and moderate -to-severe AD. 
Genetic research may consist of the analysis of one or more candidate genes or 
the analysis of genetic markers throughout the genome or analysis of the entire 
genome  (as appropriate).  
● The samples may be analyzed as part of a multi -study assessment of g enetic 
factors involved in the response to lebrikizumab  or study interventions of this 
class to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on lebrikizumab  continues but no 
longer than  15 years or other period as per local requirements.  
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
86 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
 
Hepatic Evaluation Testing  
See Section 8.2.[ADDRESS_660892] be qualified in accordance with applicable local regulations.  
Tests assayed by [CONTACT_11007] -designated central laboratory  
Hepatic Hematology Panel  Hepatitis A virus (HAV) testing:  
  Hemoglobin    HAV total antibody  
  Hematocrit    HAV IgM antibody  
  Erythrocytes (RBCs - red blood cells)  Hepatitis B virus (HBV) testing:  
  Leukocytes (WBCs - white blood cells)    Hepatitis B surface antigen (HBsAg)  
  Differential:    Hepatitis B surface antibody (anti -HBs)  
    Neutrophils, segmented    Hepatitis B core  total antibody (anti -HBc)  
    Lymphocytes    Hepatitis B core IgM antibody  
    Monocytes    HBV DNA  a 
    Basophils  Hepatitis C virus (HCV) testing:  
    Eosinophils    HCV antibody  
  Platelets    HCV RNA  a 
  Cell morphology (RBC and WBC)  Hepatitis D virus (HDV) testing:  
Hepatic Clinical Chemistry Panel    HDV antibody  
  Total bilirubin  Hepatitis E virus (HEV) testing:  
  Direct bilirubin    HEV IgG antibody  
  Alkaline phosphatase (ALP)    HEV IgM antibody  
  Alanine aminotransferase (ALT)    HEV RNA a 
  Aspartate aminotransferase (AST)  Anti -nuclear antibody (ANA)  
  Gamma -glutamyl transferase (GGT)  Anti -smooth muscle antibody (ASMA) b 
  Creatine kinase (CK)  Anti -actin antibody c 
Hepatic Coagulation Panel  Immunoglobulin IgA (quantitative)  
  Prothrombin time, INR (PT -INR)  Immunoglobulin IgG (quantitative) 
Urine Chemistry  Immunoglobulin IgM (quantitative)  
  Drug screen  Epstein -Barr virus (EBV) testing:  
Haptoglobin    EBV antibody  
a Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
b Not required if anti -actin antibody is tested . 
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
 
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
87 Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
Acetaminophen  Cytomegalovirus (CMV) testing:  
Acetaminophen protein adducts    CMV antibody  
Alkaline phosphatase isoenzymes    CMV DNA  a 
Ceruloplasmin  Herpes simplex virus (HSV) testing:  
Copper    HSV (Type 1 and 2) antibody  
Ethyl alcohol (EtOH)    HSV (Type 1 and 2) DNA  a 
Phosphatidylethanol (PEth)  Liver kidney microsomal type 1 (LKM -1) antibody  
Urine Chemistry  Microbiology  
  Ethyl glucuronide (EtG)  Culture:  
Epstein -Barr virus (EBV) testing:    Blood  
  EBV DNA  a   Urine  
 
a Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
88 10.7. Appendix 7: American Academy of Dermatology: Criteria for the 
Diagnosis and Assessment of Atopic Dermatitis   
Features to be considered in diagnosis of patients with AD: 
Essential Features —Must be present:  
 pruritus  
 eczema (acute, subacute,  chronic)  
o typi[INVESTIGATOR_73262] -specific  patterns*  
o chronic or relapsing  history  
*Patterns include : 
1) facial, neck, and extensor involvement in infants and children  
2) current or previous flexural lesions in any age group  
3) sparing of the groin and axillary regions  
Important Features —Seen in most cases, adding support to the diagnosis:  
 early age of  onset  
 atopy  
o personal and/or family  history  
o Immunoglobulin E  reactivity  
 xerosis  
 
Associated Features —These clinical associations help to suggest the diagnosis of AD 
but are too nonspecific to be used for defining or detecting AD for research and 
epi[INVESTIGATOR_29820]:  
 atypi[INVESTIGATOR_73263] ( for example , facial pallor, white dermographism, delayed 
blanch  response)  
 keratosis pi[INVESTIGATOR_22785]/pi[INVESTIGATOR_80166]/hyperlinear  palms/ichthyosis  
 ocular/periorbital  changes  
 other regional finding s (for example . perioral changes/periauricular  lesions)  
 perifollicular accentuation/lichenification/prurigo  lesions  
 
Exclusionary Features —It should be noted that a diagnosis of AD depends on 
excluding conditions, such as:  
 scabies  
 seborrheic  dermatitis  
 contact [CONTACT_8748] (irritant or  allergic)  
 ichthyoses  
 cutaneous T -cell lymphoma  
 psoriasis  
 photosensitivity  dermatoses  
 immune deficiency  diseases  
 erythroderma of other  causes  
Source: Eichenfield et al. Guidelines of care for the management of atopic dermatit is: Section 1 . 
Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol . 2014;70(2):338 -3351.   
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
89 10.8. Appendix 8: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device Deficiencies : 
Definition and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
Refer to Appendix 3 for defin itions and procedures for recording, evaluating, follow -up, and 
reporting of all events.  
 
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
90 10.9. Appendix 9: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy   
This table lists examples of infec tions that may be considered opportunistic in the context of 
biologic therapy. This table is provided to aid the investigator in recognizing infections that may 
be considered opportunistic. This list is not exhaustive. For data analysis, infections will be  
categorized by [CONTACT_81291]. (2015).  
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
91 Examples of infections that may be considered opportunistic in the setting of biologic 
therapy  
Bacterial  
 Bartonellosis (disseminated disease only)  
 Campylobacteriosis (invasive disease only)  
 Legionellosis  
 Listeriosis (invasive disease only)  
 Nocardiosis  
 Tuberculosis  
 Non-tuberculous mycobacterial disease  
 Salmonellosis (invasive disease only)  
 Shigellosis (invasive disease only)  
 Vibriosis (invasive disease due to Vibrio vulnificus ) 
Viral  
 BK virus disease including polyomavirus -associated nephropathy  
 Cytomegalovirus disease  
 Hepatitis B virus reactivation  
 Hepatitis C virus progression  
 Herpes simplex (invasive disease only)  
 Herpes zoster (any form)  
 Post-transplant lymphoproliferative disorder (Epstein -Barr virus)  
 Progressive multifocal leukoencephalopathy (PML) , John Cunningham (JC) virus  
Fungal  
 Aspergillosis (invasive disease only)  
 Blastomycosis  
 Candidiasis (invasive disease or oropharyngeal, esophageal. Not isolated lingual)  
 Coccidioidomycosis  
 Cryptococcosis  
 Histoplasmosis  
 Paracoccidioides infections  
 Penicilliosis  
 Pneumocystosis  
 Sporotrichosis  
 Other invasive molds: Mucormycosis (zygomycosis) ( Rhizopus , Mucor,  and Lichtheimia ), 
Scedosporium /Pseudallescheria boydii , Fusarium  
Parasitic  
 Leishmaniasis (visceral only)  
 Strongyloidiasis (hyperinfection syndrome or disseminated disease)  
 Microsporidiosis  
 Toxoplasmosis  
 Trypanosoma cruzi infection (Chagas’ disease progression) (disseminated disease only)  
 Cryptosporidiosis (chronic disease only)  
Source: Based on Winthrop et al. (2015).  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
92 10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific tim e periods as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These di sruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies , and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not t ypi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, upon implementation and suspension of changes). All 
approvals and notifications must be retained in the study r ecords.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely in the study and maintaining the integr ity of the study.  
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered protocol deviations if written 
sponsor approval is given.  
Screening period guidance  
If the study screening window exceeds 30 days due to the exceptional circumstances, the 
participant would be considered a screen failure and may be rescreened if  written sponsor 
approval is given.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
93 The screening procedures per the SoA in the protocol should be followed (starting at Visit 1) to 
ensure participant eligibility by [CONTACT_510938] (Visit 2). Before rescreening, the participant 
must sign a new ICF and  receive a new identification number through IWRS . 
 
Adjustments to visit windows  
Whenever possible and safe to do so, as determined by [CONTACT_093]’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance and written 
approval from the sponsor. This minimizes missing data and preserves the intended conduct of 
the study.  
 
This table describes the allowed adjustme nts to visit windows.  
Visit Number  Tolerance  
Weeks 2 -14  ±7 days  
Week 16  ±[ADDRESS_660893]-treatment safety follow -
up ([ADDRESS_660894] dose)  ±[ADDRESS_660895] extended windows, subsequent dosing should be  
a minimum of 7 days apart if the visit window is expanded due to exceptional circumstances.  
NOTE : Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site sta ff 
Documentation  
Changes to study conduct will be documented.  
Sites will identify and document the details of how participants, visit window adjustments and or 
rescreening were affected by [CONTACT_52022].  
 
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
94 10.11.  Appendix 11: Abbreviations  and Definitions   
Term  Definition  
AAULN  age adjusted ULN  
AD atopic dermatitis  
ADCT  Atopic Dermatitis Control Tool  
ADA  anti-drug antibody  
AE adverse event  
AESI  AE of special interest  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
anti-HCV  antibodies to HCV  
AST aspartate aminotransferase  
BSA  body surface area  
CDLQI  Children’s DLQI  
CI confidence interval  
COA  clinical outcome assessment  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -relate d, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form; a  printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial participant . 
CSR  clinical study report  
Device deficiencies  Equivalent to product complaint  
DLQI  Dermatology Life Quality Index  
EASI  Eczema Area and Severity Index  
eCOA  electronic COA  
EDC  electronic data capture  
enroll  The act of assigning a participant  to a treatment. Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
95 enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
F-IGA Face -IGA 
FLG filaggrin  
GCP  good clinical practice  
HBcAb  hepatitis B core antibody  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICF informed consent  form  
ICH International Council for Harmonisation  
IGA Investigator ’s Global Assessment  
IgE immunoglobulin E  
IL interleukin  
IL-4R IL-4 receptor alpha  
IL-13R1 IL-13 receptor alpha 1  
informed consent  A process by [CONTACT_9444] a participant  voluntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the study that are 
relevant to the participant’s  decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signe d and dated informed consent form . 
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceuti cal form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB/IEC institutional review board/independent ethics committee  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
96 ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a participant  (that is, the 
planned treatment regimen) rather than the actual treatment given. It  has the 
consequence that participant  assigned  to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.  
IWRS  interactive web -response system  
JAK Janus  kinase  
LOR  loricrin  
NRS  numeric rating scale 
participant  Equivalent to  CDISC  term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PDS Post-inflammatory Dyschromia Scale  
PK pharmacokinetic  
POEM  Patient -Oriented Eczema Measure  
PO-SCORAD  Patient -Oriented SCORAD  
PRO  patient -reported outcomes  
Q2W  once every [ADDRESS_660896] of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SoA schedule of activities  
TBL total bilirubin  
TCI topi[INVESTIGATOR_143180] 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
97 TCS topi[INVESTIGATOR_510907] -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a c ausal relationship 
with this treatment.  
Th2 T-helper Type [ADDRESS_660897] upper limit of normal  
WOCBP  Women of childbearing potential  
  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
98 10.12.  Appendix 1 2: Protocol Amendment History   
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment [b]: 27-April -[ADDRESS_660898] on 
the interpretation of the data generated in the clinical study.  
Overall Rationale for the Amendment:  
The main rationale for this  amendment is provided below . 
Section # and Name  [CONTACT_11029]  
1.1. Synopsis and  
3. Objectives, Endpoints, 
and Estimands  Revised the primary 
clinical research 
question and the 
attributes of the primary 
estimand.  To ensure that the primary clinical 
research question, primary estimand, 
and primary analysis are in alignment. 
The original treatment policy estimand 
is not aligned with the as -observed 
analysis . 
6.6. Continued Access to 
Study Intervention after 
the End of the Study  Updated to allow 
continued access to 
lebrikizumab for 
eligible participants 
who complete Visit 9 
(Week 24)  Provide an uninterrupted supply of 
lebrikizumab to qualified participants, 
via the Continued Access addendum, 
until lebrikizumab is comm ercially 
available in the US  
6.8.1 Permitted 
Treatments and 
Procedures  Added use of high -
potency TCS up to 10 
days Permitting high -potency TCS for up to 
10 days is similar to the real -world 
setting  
6.8.2 Prohibited 
Treatments and 
Procedures  Comment updated for 
topi[INVESTIGATOR_510908]-
potency TCS  for >[ADDRESS_660899] 
‘may’  The intent is to conve y that the use of 
emollients is not mandatory but 
recommended  
6.8.4 Topi[INVESTIGATOR_510909] -
potency TCS > 10 days  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
99 Section # and Name  [CONTACT_11029]  
6.8.5 Rescue treatment 
for Atopic Dermatitis  Added use of high -
potency TCS > 10 days  Permitting high -potency TCS for > 10 
days will be considered as rescue 
medication  
7.1. Discontinuation of 
Study Intervention  Added “ the participant 
requires rescue 
medication treatment 
for symptoms of AD in 
the treatment period ”  
Removed “ participant  
requir es high-potency 
TCS or systemic 
treatment for symptoms 
of AD in the treatment 
period ” Alignment with rescue treatment for 
Atopic Dermatitis  
9.2. Analyses Sets  Added “population” to 
describe ITT and Safety 
analysis set  Clarification  
9.3.2. Primary 
Endpoint(s)/Estimand(s) 
Analysis  Revised the primary 
clinical question of 
interest  To align primary estimand with primary 
analysis. The original treatment policy 
estimand is not aligned with the as -
observed analysis  
9.3.3.  Secondary 
Endpoint(s)/Estimand(s ) 
Analysis  Removed reference to 
the treatment policy 
strategy for secondary 
endpoints.  To clarify that secondary endpoints will 
be analyzed similarly to the primary 
endpoint of the primary estimand, that 
is, using all observed data. The original 
treatment policy estimand is not aligned 
with the as -observed analysis  
9.3.4 . Exploratory 
Endpoint(s) Analysis  Removed reference to 
the treatment policy 
strategy for exploratory 
endpoints  To clarify that exploratory endpoints 
will be analyzed similarly to the primary 
endpoint of the primary estimand, that 
is, using all observed data. The original 
treatment policy estimand is not aligned 
with the as -observed analysis  
9.5. Sample Size 
Determ ination  Replaced “power” with 
“probability”  Correction  
10.3.6. Regulatory 
Reporting Requirements  
SAE Regulatory 
Reporting  Added text for 
suspected unexpected 
serious adverse 
reactions  Alignment with latest guidance  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
100 Section # and Name  [CONTACT_510940], therefore they have not 
been individually summarized  
Amendment [a]: 12-October -2022   
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
To correct the Schedule of Activities.  
 
Section # and 
Name  [CONTACT_9353] 1.3 
Schedule of 
Activities   Collection  of ADCT  added 
in V4/W4  
 Post-treatment Follow -Up 
Urine pregnancy removed 
from V801   Inadvertently excluded in prior 
version  
 
 Inadvertently included in prior 
version, not required as 
participant s no longer receiving 
study drug at V801   
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
101 11. References   
Adelekun A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: An updated 
evaluation and analysis. J Am Acad Dermatol . 2021;84(1):194 -196. https:// doi.org/ 
10.1016/j.jaad.2020.04.084  
Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. Eur 
Cytokine Netw . 2013;24(1):37 -44. https://doi.org/10.1684/ecn.2013.0333  
Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference  
and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology . 
2015;230(1):27 33.  https://doi.org/10.1159/000365390  
Bieber T. Atopic dermatitis. N Engl J Med . 2008;358(14):1483 -1494. 
https://doi.org/.1056/NEJMra074081  
Bieber T , Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma 
Rep. 2009;9(4):291 -294. https://doi.org/10.1007/s11882 -009-0041 -2 
Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and 
stratified medi cine. Allergy . 2012;67(12):1475 -1482. https://doi.org/10.1111/all.[ZIP_CODE]  
Bieber T, Straeter B. Off -label prescriptions for atopic dermatitis in Europe. Eur J Aller Clin 
Immunol. 2015;70(1):6 -11. https://doi.org/10.1111/all.[ZIP_CODE]  
Brunner PM, Guttman -Yassky E . Racial differences in atopic dermatitis. Ann Allergy Asthma 
Immunol . 2019;122(5):449 -455. https://doi.org/ 10.1016/j.anai.2018.11.015  
Charman CR, Venn AJ, Williams HC. The patient -oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients’ 
perspective. Arch Dermatol . 2004;140(12):1513 -1519. 
https://doi.org/10.1001/arch derm.140.12.1513  
Chen V, Akhtar S, Zheng C, et al. Assessment of changes in diversity in dermatology clinical 
trials between 2010 -2015 and 2015 -2020: A Systematic Review. JAMA Dermatol . 
2022 ;158(3):288 -292. https://doi.org/ 10.1001/jamadermatol.2021.5596  
Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America Study: A 
Cross -Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the 
US Adult Population. J Invest Dermatol . 2019;139(3):583 -590. doi: 10.1016/ j.jid.2018.08.028.  
Choy DF, Hsu DK, Seshasayee D, et al. Comparative transcriptomic analyses of atopic 
dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol . 
2012;130(6):1335 -1343. https://doi.org/10.1016/j.jaci.2012.06.0 44 
Davis EC, Callender VD. Postinflammatory hyperpi[INVESTIGATOR_371]: a review of the epi[INVESTIGATOR_623], 
clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol . 2010;3(7):20 -
31  
Ebede T, Papi[INVESTIGATOR_3694] A. Disparities in dermatology educational resources. J Am Acad Dermatol . 
2006;55(4):687 -690. https://doi.org/ 10.1016/j.jaad.2005.10.068  
Eichenfield LF et al. Guidelines of care for the management of atopic dermatitis: section 1. 
Diagnosis a nd assessment of atopic dermatitis. J Am Acad Dermatol . 2014;70(2):338 -351. 
10.1016/j.jaad.2013.10.010  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
102 Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. 
Curr Allergy Asthma Rep . 2004;4(4):276 -284. https://doi.org/10.1007/s11882 -004-0071 -8 
Faye O, Meledie N'Djong AP, Diadie S, et al. Validation of the Patient -Oriented SCORing for 
atopic dermatitis tool for black skin. J Eur Acad Dermatol Venereol . 2020;34(4):795 -799. 
https://doi.org/ 10.1111/jdv.[ZIP_CODE]  
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupi[INVESTIGATOR_12458]: A review of its use in the 
treatment of atopic dermatitis. Am Acad Dermatol. 2018;78(3):S28 -S36. 
https://doi.org/10.1016/j.jaad.2017.12.022  
Guttman -Yassky E, Blauvelt A, Eichenfield LF, et al. Effica cy and safety of lebrikizumab, a 
high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a Phase 
2b randomized clinical trial. JAMA Dermatol . 2020;156(4):411 -420. 
https://doi.org/10.1001/jamadermatol.2020.0079  
Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL -12 and IL -13 in atopic 
dermatitis. J Allergy Clin Immunol . 1996;98(1):225 -231. https://doi.org/10.1016/s0091 -
6749(96)[ZIP_CODE] -4 
Hanifin JM, Thurston M, Omoto M, et al. EASI Evaluator Group. The eczema area and severity 
index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol . 2001;10(1):11 -18. 
https://doi.org/10.1034/j.1600 -0625.2001.100102.x  
Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults:  a population -
based study. Clin Exp Allergy . 2007;37(4):526 -35. doi: 10.1111/j.1365 -2222.2007.[ZIP_CODE].x.  
He JQ, Chan -Yeung M, Becker AB, et al. Genetic variants of the IL13 and IL4 genes and atopic 
diseases in at -risk children. Genes Immun . 2003;4(5):385 -389. 
https://doi.org/10.1038/sj.gene.6363985  
High, WA, Tomasini CF, Argenziano G, Zalaudek I. Basic principles  of dermatology . In 
Bolognia JL, Jorizzo JL, Schaffer JV., editors. Dermatology (3rd ed.) . China: Elsevier ;2012:pp.8  
Hongbo Y, Thomas CL, Harrison MA , et al. Translating the science of quality of life into 
practice: What do dermatology life quality index scores mean? J Invest Dermatol . 
2005;125(4):659 -664. https://doi.org/10.1111/j.0022 -202x.2005.[ZIP_CODE].x  
Hummelshoj T, Bodtger U, Datta P, et al. Association between an interleukin -13 promoter 
polymorphism and atopy. Eur J Immunogenet . 2003;30(5):355 -359. 
https://doi.org/10.1046/j.1365 -2370.2003.[ZIP_CODE].x  
Ibraheim MK, Gupta R, Dao H, et al. Evaluating skin of c olor education in dermatology 
residency programs: data from a national survey. Clin Dermatol . 202125:S0738 -
081X(21)[ZIP_CODE] -1. https://doi.org/ 10.1016/j.clindermatol.2021.11.015  
Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in  lesional 
skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT -PCR. Clin Exp 
Allergy . 2003;33(12):1717 -1724. https://doi.org/10.1111/j.1365 -2222.2003.[ZIP_CODE].x  
Jungersted JM, Høgh JK, Hellgren LI, et al. Ethnicity and stratum corneum ceramides. Br J 
Dermatol . 2010;163(6):1169 -1173. https://doi.org/ 10.1111/j.1365 -2133.2010.[ZIP_CODE].x  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
103 Kaufman BP, Guttman -Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic 
groups -Variations in epi[INVESTIGATOR_623], genetics, clinical presenta tion and treatment. Exp Dermatol . 
2018;27(4):340 -357. https://doi.org/ 10.1111/exd.[ZIP_CODE]  
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol . 2002;147(suppl 62):25 -54. 
Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in 
health -related quality of life. Int J Dermatol . 2002;41(3):151 -8. doi: 10.1046/j.1365 -
4362.2002.[ZIP_CODE].x.  
Kurtti A, Austin E, Jagdeo J. Representation of skin colo r in dermatology -related google image 
searches. J Am Acad Dermatol . 2022;86(3):705 -708. https://doi.org/ 10.1016/j.jaad.2021.03.036  
La Grutta S, Richiusa P, Pi[INVESTIGATOR_81229] G, et al. CD4(+)IL -13(+) cells in peripheral blood well 
correlates with the severity of a topic dermatitis in children. Allergy . 2005;60(3):391 -395. 
https://doi.org/10.1111/j.1398 -9995.2005.[ZIP_CODE].x  
Muizzuddin N, Hellemans L, Van Overloop L, et al. Structural and functional differences in 
barrier properties of African American, Caucasian and Eas t Asian skin. J Dermatol Sci . 
2010;59(2):123 -8. doi: 10.1016/j.jdermsci.2010.06.003.  
Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL -[ADDRESS_660900] dermatitis. J Allergy Clin Immunol . 2006;118(4):930 -937. 
https://doi.org/10.1016/j.jaci.2006.07.015  
Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of 
newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep 
Outcomes . 2019;3(1):42. https://doi.org/ 10.1186/s41687 -019-0128 -z. 
Noda S, Suárez -Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines 
features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin 
Immunol . 2015;13 6(5):1254 -1264. https://doi.org/ 10.1016/j.jaci.2015.08.015  
Novak N, Kruse S, Kraft S, et al. Dichotomic nature of atopic dermatitis reflected by [CONTACT_81292][INVESTIGATOR_81231] -4/interl eukin -13 receptor gene: the dichotomy of extrinsic and intrinsic atopic 
dermatitis. J Invest Dermatol . 2002;119(4):870 -875. https://doi.org/10.1046/j.1523 -
1747.2002.[ZIP_CODE]  
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient -perceived control of ato pic 
dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr 
Med Res Opin . 2020;36(3):367 -376. https://doi.org/ 10.1080/03007995.2019.1699516.  
Price KN, Hsiao JL, Shi VY. Race and ethnicity gaps in global hidradenitis suppurativa clinical 
trials.  Dermatology . 2021;237(1):97 -102. https://doi.org/ 10.1159/[ADDRESS_660901] 
CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Derm atol. 2006;126(5):1043 
1051. https://doi.org/10.1038/sj.jid.5700085  
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics . 1993;4(5):353 365.  
https://doi.org/10.2165/00019053 -199304050 -[ZIP_CODE]  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
104 Sacotte R, Silverberg J I. Epi[INVESTIGATOR_81232] . Clin Dermatol . 2018 ; 
36(5):595–605. https://doi.org/ 10.1016/j.clindermatol.2018.05.007  
Sangha AM. Dermatological Conditions in SKIN OF COLOR -: Managing atopic dermatitis. J 
Clin Aesthet Dermatol . 2021;14([ADDRESS_660902] 1):S20 -S22.  
Schwartzman G, Lei D, Ahmed A, et al. Longitudinal course and phenotypes of health -related 
quality of life in adults w ith atopic dermatitis. Clin Exp Dermatol . 2022;47(2):359 -372. 
https://doi.org/ 10.1111/ced.[ZIP_CODE]  
Seegräber M, Srour J, Walter A, et al. Dupi[INVESTIGATOR_510910]. Expert Rev 
Clin Pharmacol. 2018;11(5):467 -474. https://doi.org/10.1080/1751 2433.2018.1449642  
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other 
health and demographic factors: a US population -based study. J Allergy Clin Immunol . 
2013;132(5):1132 -8. https://doi.org/ 10.1016/j.jaci.2013.08.031  
Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in 
united states adults. J Eur Acad Dermatol Venereol . 2019;33(7):1341 -1348. 
https://doi.org/ 10.1111/jdv.[ZIP_CODE]  
Silverberg JI, DeLozier A, Sun L, et al. Psychometric  properties of the itch numeric rating scale, 
skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate -
to-severe atopic dermatitis. Health Qual Life Outcomes . 2021;19(1):247. 
https://doi.org/ 10.1186/s12955 -021-[ZIP_CODE] -8 
Simon D, Wollenberg A, Renz H, Simon HU. Atopic dermatitis: Collegium Internationale 
Allergologicum (CIA) update 2019. Int Arch Allergy Immunol . 2019;178(3):207 -218. 
https://doi.org/10.1159/000497383  
Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool 
(ADCT©) using a longitudinal survey of biologic -treated patients with atopic dermatitis. BMC 
Dermatol . 2019;19(1):15. https://doi.org/ 10.1186/s12895 -019-0095 -3 
Stalder JF, Barbarot S, Wollenberg A,  et al.  PO-SCORAD Investigators Group. Patient -Oriented 
SCORAD (PO -SCORAD): a new self -assessment scale in atopic dermatitis validated in Europe. 
Allergy . 2011;66(8):1114 -21. https://doi.org/ 10.1111/j.1398 -9995.2011.[ZIP_CODE].x  
Suárez -Fariñas M, Dhingra N, Git tler J, et al. Intrinsic atopic dermatitis shows similar TH2 and 
higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin 
Immunol . 2013;132(2):361 -370. https://doi.org/10.1016/j.jaci.2013.04.046  
Tazawa T, Sugiura H, Sugiura Y , Uehara M. Relative importance of IL -4 and IL -13 in lesional 
skin of atopic dermatitis. Arch Dermatol Res . 2004;295(11):459 -464. 
https://doi.org/10.1007/s00403 -004-0455 -6 
Van Bever HPS, Llanora G. Features of childhood atopic dermatitis. Asian Pac J Aller gy 
Immunol . 2011;29(1):15 -24. 
Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control 
among adults with a history of moderate to severe atopic dermatitis. J Dermatol.  
2018;45(2):150 -157. https://doi.org/ 10.1111/1346 -8138.[ZIP_CODE]  
Approved on 29 Sep 2023 GMT
CONFIDENTIAL  J2T-MC-KGBP (c) 
105 Weidinger S, Novak N. Atopic dermatitis. Lancet . 2016;387([ZIP_CODE]):1109 -1122. 
https://doi.org/10.1016/S0140 -6736(15)[ZIP_CODE] -X 
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers . 2018;4(1):1. 
https://doi.org/10 .1038/s41572 -018-0001 -z 
Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in 
patients with atopic dermatitis. J Allergy Clin Immunol . 2016;138(2):336 -349. 
https://doi.org/10.1016/j.jaci.2016.06.010  
Williams H, Stewart A , von Mutius E, et al. Is eczema really on the increase worldwide? J 
Allergy Clin Immunol. 2008;121(4):947 -954.e15. https://doi.org/10.1016/j.jaci.2007.11.004  
Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapi[INVESTIGATOR_41377] -mediated inflammatory diseases: consensus recommendations for infection reporting 
during clinical trials and postmarketing surveillance. Ann Rheum Dis . 2015;74(12):2107 -2116. 
https://doi.org/10.1136/annrheumdis -2015 -207841  
Yosipovitch G, Reaney M, Mas tey V ,et al. Peak Pruritus Numerical Rating Scale: psychometric 
validation and responder definition for assessing itch in moderate -to-severe atopic dermatitis. Br 
J Dermatol . 2019 ; 181(4):761 -769. https://doi.org/10.1111/bjd.[ZIP_CODE]  
Yosipovitch  G, Rams  A, Baldasaro  J, et al. Content Validity And Assessment of the 
psychometric properties and score interpretation of a Sleep -Loss Scale score in atopic dermatitis.  
Revolutionizing Atopic Dermatitis  – December 2021  
Zhao CY, Wijayanti A, Doria MC, et al. The relia bility and validity of outcome measures for 
atopic dermatitis in patients with pi[INVESTIGATOR_427409]: A grey area. Int J Womens Dermatol . 
2015;1(3):150 -154. https://doi.org/ 10.1016/j.ijwd.2015.05.002  
Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic 
dermatitis. J Allergy Clin Immunol . 2006;118(1):226 -32. 
https://doi.org/ 10.1016/j.jaci.2006.02.031  
Approved on 29 Sep 2023 GMT
Signature [CONTACT_11032]-CLIN-093431 v2.0
Signature [CONTACT_11032]-CLIN-093431 v2.0Approval
29-Sep-2023 13:00:27 GMT[PHONE_006]
Approval
29-Sep-2023 14:54:56 GMT[PHONE_006]
Approved on 29 Sep 2023 GMT
[COMPANY_003]
[COMPANY_003]